{
  "file_name": "CUAD_v1/full_contract_pdf\\Part_I\\Development\\RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement.pdf",
  "annotations": [
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Sanofi",
      "page_number": 0,
      "words": [
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Sanofi and RevMed are referred to in this Agreement individually as a \"Party\" and collectively as the \"Parties.\"",
      "page_number": 0,
      "words": [
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Revolution Medicines, Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Aventis, Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "RevMed",
      "page_number": 0,
      "words": [
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Agreement Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "June 8, 2018",
      "page_number": 0,
      "words": [
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Effective Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effectiveÂ ",
      "answer_text": "June 8, 2018",
      "page_number": 0,
      "words": [
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Expiration Date_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article XII, shall continue in full force and effect until the expiration of Sanofi's payment obligations under Article IX or the Profit/Loss Share Agreement, whichever is later (the \"Term\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Expiration Date_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "The term of this Agreement shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article XII, shall continue in full force and effect until the expiration of Sanofi's payment obligations under Article IX or the Profit/Loss Share Agreement, whichever is later (the \"Term\").",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Governing Law_0",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement shall be governed by and construed in accordance with the laws of the State of New York without reference to any rules of conflict of laws.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Governing Law_0",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Letter shall be governed by and construed in accordance with the laws of the State of New York without reference to any rules of conflict of laws.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Non-Compete_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "If after [***]: (i) Sanofi or its Affiliates, alone or with or through a Third Party, develop, manufacture or commercialize a Competing Product and (ii) Sanofi or its Affiliates have not commenced a Registrational Clinical Trial for a Product prior to commencing the activities in Section 12.2(d)(i), RevMed may terminate this Agreement effective [***] after it delivers written notice to Sanofi that it is exercising its rights under this Section 12.2(d) unless Sanofi elects in writing within such [***] period to [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Non-Compete_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "If after [***]: (i) Sanofi or its Affiliates, alone or with or through a Third Party, develop, manufacture or commercialize a Competing Product and (ii) Sanofi or its Affiliates have not commenced a Registrational Clinical Trial for a Product prior to commencing the activities in Section 12.2(d)(i), RevMed may terminate this Agreement effective [***] after it delivers written notice to Sanofi that it is exercising its rights under this Section 12.2(d) unless Sanofi elects in writing within such [***] period to [***].",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Non-Compete_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Except pursuant to or as expressly permitted by this Agreement, RevMed shall not, shall cause its Affiliates not to, conduct or agree to conduct, outside of the Collaboration, on its own or together with one or more Third Parties, the Research, Development or Commercialization of any product that contains a SHP2 Inhibitor, including any SHP1-SHP2 Dual Inhibitor that [***]. For purposes of this Section, [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Non-Compete_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Except pursuant to or as expressly permitted by this Agreement, RevMed shall not, shall cause its Affiliates not to, conduct or agree to conduct, outside of the Collaboration, on its own or together with one or more Third Parties, the Research, Development or Commercialization of any product that contains a SHP2 Inhibitor, including any SHP1-SHP2 Dual Inhibitor that [***]. For purposes of this Section, [***].",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an exclusive (even as to RevMed and its Affiliates), royalty-bearing license (which shall be sub-licensable solely as provided in Section 3.4) under the RevMed Licensed Technology, to Research, Develop, Manufacture, use, sell, offer for sale, import and otherwise Commercialize and exploit Products (including, for clarity, any Companion Diagnostics with respect to such Products) in the Field in the Licensed Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an exclusive (even as to RevMed and its Affiliates), royalty-bearing license (which shall be sub-licensable solely as provided in Section 3.4) under the RevMed Licensed Technology, to Research, Develop, Manufacture, use, sell, offer for sale, import and otherwise Commercialize and exploit Products (including, for clarity, any Companion Diagnostics with respect to such Products) in the Field in the Licensed Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Exclusivity_0",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an exclusive option, under the Patent Rights and Know-How claiming or embodied in the [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "If Sanofi provides a Notice of Interest to RevMed within [***], then (i) RevMed shall, upon request of Sanofi, provide Sanofi with reasonable access to all other then-existing Know-How in RevMed's Control that exists in either paper or electronic form and pertains to the relevant SHP1-SHP2 Dual Inhibitor and (ii) the Parties shall negotiate exclusively in good faith and on a commercially reasonable basis the terms of a definitive agreement under which Sanofi would be granted SHP1-SHP2 Dual Inhibitor License Rights for [***] after RevMed receives such Notice of Interest (such period, the \"SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "If Sanofi provides a Notice of Interest to RevMed within [***], then (i) RevMed shall, upon request of Sanofi, provide Sanofi with reasonable access to all other then-existing Know-How in RevMed's Control that exists in either paper or electronic form and pertains to the relevant SHP1-SHP2 Dual Inhibitor and (ii) the Parties shall negotiate exclusively in good faith and on a commercially reasonable basis the terms of a definitive agreement under which Sanofi would be granted SHP1-SHP2 Dual Inhibitor License Rights for [***] after RevMed receives such Notice of Interest (such period, the \"SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Termination For Convenience_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "Sanofi may terminate this Agreement (A) in its entirety by providing [***] written notice of termination to RevMed or (B) on a country-by-country or Product-by-Product basis by providing [***] written notice of termination to RevMed; provided that if Sanofi desires to terminate this Agreement under this Section 12.2(a)(i)B only with respect to the U.S. (for all Products or one or more Products), Sanofi shall provide [***] written notice of termination to RevMed.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Termination For Convenience_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "Sanofi may terminate this Agreement (A) in its entirety by providing [***] written notice of termination to RevMed or (B) on a country-by-country or Product-by-Product basis by providing [***] written notice of termination to RevMed; provided that if Sanofi desires to terminate this Agreement under this Section 12.2(a)(i)B only with respect to the U.S. (for all Products or one or more Products), Sanofi shall provide [***] written notice of termination to RevMed.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If [***] (such determination, the \"SHP1-SHP2 Dual Inhibitor Licensing Decision\" and such Third Party's rights, the \"SHP1-SHP2 Dual Inhibitor License Rights\"), then prior to commencing any negotiations with any Third Party with regard to any SHP1-SHP2 Dual Inhibitor License Rights, RevMed shall promptly notify Sanofi in writing of such SHP1-SHP2 Dual Inhibitor Licensing Decision and provide to Sanofi a detailed summary of the data then in RevMed's Control regarding the relevant SHP1-SHP2 Dual Inhibitor.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If [***] (such determination, the \"SHP1-SHP2 Dual Inhibitor Licensing Decision\" and such Third Party's rights, the \"SHP1-SHP2 Dual Inhibitor License Rights\"), then prior to commencing any negotiations with any Third Party with regard to any SHP1-SHP2 Dual Inhibitor License Rights, RevMed shall promptly notify Sanofi in writing of such SHP1-SHP2 Dual Inhibitor Licensing Decision and provide to Sanofi a detailed summary of the data then in RevMed's Control regarding the relevant SHP1-SHP2 Dual Inhibitor.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "During the Term prior to the Option exercise by Sanofi, RevMed shall provide to Sanofi any additional information Controlled by RevMed that is reasonably requested by Sanofi in order to assist Sanofi in determining whether to exercise its Option. If Sanofi so exercises its Option pursuant to this Section 3.1(b)(ii), [***]. U",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "During the Term prior to the Option exercise by Sanofi, RevMed shall provide to Sanofi any additional information Controlled by RevMed that is reasonably requested by Sanofi in order to assist Sanofi in determining whether to exercise its Option. If Sanofi so exercises its Option pursuant to this Section 3.1(b)(ii), [***]. U",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If Sanofi provides a Notice of Interest to RevMed within [***], then (i) RevMed shall, upon request of Sanofi, provide Sanofi with reasonable access to all other then-existing Know-How in RevMed's Control that exists in either paper or electronic form and pertains to the relevant SHP1-SHP2 Dual Inhibitor and (ii) the Parties shall negotiate exclusively in good faith and on a commercially reasonable basis the terms of a definitive agreement under which Sanofi would be granted SHP1-SHP2 Dual Inhibitor License Rights for [***] after RevMed receives such Notice of Interest (such period, the \"SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If Sanofi provides a Notice of Interest to RevMed within [***], then (i) RevMed shall, upon request of Sanofi, provide Sanofi with reasonable access to all other then-existing Know-How in RevMed's Control that exists in either paper or electronic form and pertains to the relevant SHP1-SHP2 Dual Inhibitor and (ii) the Parties shall negotiate exclusively in good faith and on a commercially reasonable basis the terms of a definitive agreement under which Sanofi would be granted SHP1-SHP2 Dual Inhibitor License Rights for [***] after RevMed receives such Notice of Interest (such period, the \"SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period\").",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "Sanofi may exercise its Option at any time during the Term by providing RevMed with written notice of such exercise",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "respect to a SHP1-SHP2 Dual Inhibitor during the SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period. If (x) Sanofi does not provide a Notice of Interest within [***] or (y) Sanofi does provide a Notice of Interest within [***] but Parties have not entered into an agreement under which Sanofi is granted SHP1-SHP2 Dual Inhibitor License Rights prior to the expiration of the SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period, then RevMed shall have no further obligations to Sanofi with respect to such SHP1-SHP2 Dual Inhibitor Products, and RevMed shall have the right to enter into negotiations and execute an agreement with a Third Party under which such Third Party is granted the SHP1-SHP2 Dual Inhibitor License Rights [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "respect to a SHP1-SHP2 Dual Inhibitor during the SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period. If (x) Sanofi does not provide a Notice of Interest within [***] or (y) Sanofi does provide a Notice of Interest within [***] but Parties have not entered into an agreement under which Sanofi is granted SHP1-SHP2 Dual Inhibitor License Rights prior to the expiration of the SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period, then RevMed shall have no further obligations to Sanofi with respect to such SHP1-SHP2 Dual Inhibitor Products, and RevMed shall have the right to enter into negotiations and execute an agreement with a Third Party under which such Third Party is granted the SHP1-SHP2 Dual Inhibitor License Rights [***].",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "of the data then in RevMed's Control regarding the relevant SHP1-SHP2 Dual Inhibitor. Sanofi shall notify RevMed in writing (a \"Notice of Interest\"), within [***] after Sanofi's receipt of such notice, if Sanofi desires to enter into negotiations with RevMed of the terms under which Sanofi would obtain SHP1-SHP2 Dual Inhibitor License Rights.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "of the data then in RevMed's Control regarding the relevant SHP1-SHP2 Dual Inhibitor. Sanofi shall notify RevMed in writing (a \"Notice of Interest\"), within [***] after Sanofi's receipt of such notice, if Sanofi desires to enter into negotiations with RevMed of the terms under which Sanofi would obtain SHP1-SHP2 Dual Inhibitor License Rights.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If RevMed wishes to exercise its one-time Co-Promotion Option, it shall so notify Sanofi in writing at least [***] prior to the anticipated launch of such Product in the Co-Promotion Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an exclusive option, under the Patent Rights and Know-How claiming or embodied in the [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "pon Sanofi's exercise of the Option, [***] accordingly subject to the license granted to Sanofi under Section 3.1(a) and the payment obligations therefor pursuant to this Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "For clarity, once RevMed has exercised its Co- Promotion Option pursuant to this Section 8.7(b), RevMed's right to co-promote Products shall apply to all other existing and subsequent Products in the Co-Promotion Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "For clarity, once RevMed has exercised its Co- Promotion Option pursuant to this Section 8.7(b), RevMed's right to co-promote Products shall apply to all other existing and subsequent Products in the Co-Promotion Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "Sanofi shall have the first right, but not the obligation, through counsel of its choosing, to negotiate and obtain a license with respect to such Third Party intellectual property right and shall provide RevMed with a copy of such license if it obtains such a license (to the extent permitted by the terms of such license, provided that Sanofi shall use Commercially Reasonable Efforts to obtain such permission to provide such copy).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "Sanofi shall have the first right, but not the obligation, through counsel of its choosing, to negotiate and obtain a license with respect to such Third Party intellectual property right and shall provide RevMed with a copy of such license if it obtains such a license (to the extent permitted by the terms of such license, provided that Sanofi shall use Commercially Reasonable Efforts to obtain such permission to provide such copy).",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If Sanofi provides such Notice of Interest during [***], then RevMed shall not negotiate with any Third Party the terms under which such Third Party would obtain any development or commercialization rights with respect to a SHP1-SHP2 Dual Inhibitor during the SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If Sanofi provides such Notice of Interest during [***], then RevMed shall not negotiate with any Third Party the terms under which such Third Party would obtain any development or commercialization rights with respect to a SHP1-SHP2 Dual Inhibitor during the SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If (i) RevMed does not provide the above election notice in compliance with the requirements of this Section 8.7(b), or (ii) RevMed provides notice to Sanofi that it does not intend to exercise its one-time Co-Promotion Option, then RevMed shall be deemed to have waived such one-time right to co-promote any and all Products in the Co-Promotion Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If (i) RevMed does not provide the above election notice in compliance with the requirements of this Section 8.7(b), or (ii) RevMed provides notice to Sanofi that it does not intend to exercise its one-time Co-Promotion Option, then RevMed shall be deemed to have waived such one-time right to co-promote any and all Products in the Co-Promotion Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Change Of Control_0",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "RevMed shall pay Sanofi such royalties until the earlier of (x) expiration of the Post-Termination Royalty Term therefor and (y) a Change of Control of Sanofi.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Change Of Control_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "RevMed will notify Sanofi in writing as soon as possible after RevMed announces publicly any information regarding any proposed Change of Control of RevMed (or if the Change of Control will not be publicly announced, then no later than [***] after the signing of the Change of Control).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Change Of Control_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "RevMed will notify Sanofi in writing as soon as possible after RevMed announces publicly any information regarding any proposed Change of Control of RevMed (or if the Change of Control will not be publicly announced, then no later than [***] after the signing of the Change of Control).",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Change Of Control_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Sanofi will have the option to either (A) terminate this Agreement in its entirety upon written notice to RevMed provided to RevMed within [***] of the effective date of such Change of Control; or (B) [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Change Of Control_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Sanofi will have the option to either (A) terminate this Agreement in its entirety upon written notice to RevMed provided to RevMed within [***] of the effective date of such Change of Control; or (B) [***].",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "all research and development assets and operations of the Acquired Party Family, in each case relating to SHP2 Inhibitors and Products, remain with the Acquired Party Family and are not licensed or otherwise transferred to the Acquiror Party Family for any purpose; (C) the scientific and Development activities with respect to SHP2 Inhibitors and Products of the Acquired Party Family and Competing Products of the Acquiror Family (if any) are maintained separate and distinct, and (D) there is no exchange of Know-How relating to SHP2 Inhibitors and Products between the Acquired Party Family and the Acquiror Family. Any attempted assignment not in accordance with this Section 15.2 shall be null and void and of no legal effect.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "all research and development assets and operations of the Acquired Party Family, in each case relating to SHP2 Inhibitors and Products, remain with the Acquired Party Family and are not licensed or otherwise transferred to the Acquiror Party Family for any purpose; (C) the scientific and Development activities with respect to SHP2 Inhibitors and Products of the Acquired Party Family and Competing Products of the Acquiror Family (if any) are maintained separate and distinct, and (D) there is no exchange of Know-How relating to SHP2 Inhibitors and Products between the Acquired Party Family and the Acquiror Family. Any attempted assignment not in accordance with this Section 15.2 shall be null and void and of no legal effect.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Neither Party may assign this Agreement or any of its rights or obligations hereunder, except as expressly permitted hereunder, or delegate any of its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part, without the consent of the other Party, except as follows:\n\n(i) Sanofi may, without consent of RevMed, assign this Agreement or its rights and obligations hereunder in whole or in part to any Affiliate of Sanofi, and RevMed may, with the consent of Sanofi (not to be unreasonably withheld, delayed or conditioned), assign this Agreement or its rights and obligations hereunder in whole or in part to any Affiliate of RevMed;",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Neither Party may assign this Agreement or any of its rights or obligations hereunder, except as expressly permitted hereunder, or delegate any of its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part, without the consent of the other Party, except as follows:\n\n(i) Sanofi may, without consent of RevMed, assign this Agreement or its rights and obligations hereunder in whole or in part to any Affiliate of Sanofi, and RevMed may, with the consent of Sanofi (not to be unreasonably withheld, delayed or conditioned), assign this Agreement or its rights and obligations hereunder in whole or in part to any Affiliate of RevMed;",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Sanofi shall have the right to grant sublicenses (through multiple tiers) under the rights granted to it under Section 3.1 to one or more Third Parties (i) outside of the United States, and (ii) in the United States; provided that for purposes of subsection (ii), Sanofi shall not sublicense substantially all of the rights granted to it under Section 3.1 in the United States to Third Parties without RevMed's prior written consent, such consent not to be unreasonably withheld, delayed or conditioned.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Sanofi shall have the right to grant sublicenses (through multiple tiers) under the rights granted to it under Section 3.1 to one or more Third Parties (i) outside of the United States, and (ii) in the United States; provided that for purposes of subsection (ii), Sanofi shall not sublicense substantially all of the rights granted to it under Section 3.1 in the United States to Third Parties without RevMed's prior written consent, such consent not to be unreasonably withheld, delayed or conditioned.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Except as part of a transaction permitted under this Section 15.2, in no event shall RevMed assign or transfer, or agree to assign or transfer to any Third Party, any or all of the RevMed Licensed Patents without the consent of Sanofi, not be unreasonably withheld or conditioned.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Except as part of a transaction permitted under this Section 15.2, in no event shall RevMed assign or transfer, or agree to assign or transfer to any Third Party, any or all of the RevMed Licensed Patents without the consent of Sanofi, not be unreasonably withheld or conditioned.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "In the case of RevMed, the intellectual property owned or controlled by any such Acquiror or its Acquiror Family prior to the applicable Change of Control or other similar transaction immediately prior to such acquisition (other than as a result of a license from the acquired Party) or is thereafter developed outside the scope of this Agreement in accordance with this Agreement shall be excluded from the RevMed Licensed Technology, in each case only for so long as the remainder of the conditions of this Section 15.2 are met, and the Acquiror Family shall be excluded from \"Affiliate\" solely for purposes of the applicable components of the intellectual property definitions set forth herein, in all such cases if and only if: (A) the acquired Party remains a wholly-owned subsidiary of the Acquiror; (B) all intellectual property of the Acquired Party Family and",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "In the case of RevMed, the intellectual property owned or controlled by any such Acquiror or its Acquiror Family prior to the applicable Change of Control or other similar transaction immediately prior to such acquisition (other than as a result of a license from the acquired Party) or is thereafter developed outside the scope of this Agreement in accordance with this Agreement shall be excluded from the RevMed Licensed Technology, in each case only for so long as the remainder of the conditions of this Section 15.2 are met, and the Acquiror Family shall be excluded from \"Affiliate\" solely for purposes of the applicable components of the intellectual property definitions set forth herein, in all such cases if and only if: (A) the acquired Party remains a wholly-owned subsidiary of the Acquiror; (B) all intellectual property of the Acquired Party Family and",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_1",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Any attempted assignment not in accordance with this Section 15.2 shall be null and void and of no legal effect.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Either Party may, without consent of the other Party, assign this Agreement in whole to (i) in the case of RevMed, its successor in interest or assignee or purchaser, as applicable, in the case of a Change of Control or (ii) in the case of Sanofi, its successor in interest or assignee or purchaser, as applicable, in connection with the sale of all or substantially all of its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Either Party may, without consent of the other Party, assign this Agreement in whole to (i) in the case of RevMed, its successor in interest or assignee or purchaser, as applicable, in the case of a Change of Control or (ii) in the case of Sanofi, its successor in interest or assignee or purchaser, as applicable, in connection with the sale of all or substantially all of its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "No later than the Initiation of the first Registrational Clinical Trial for the first Product, Sanofi and RevMed shall enter into a profit/loss share agreement (the \"Profit/Loss Share Agreement\") pursuant to which the Parties shall equally share the Net Profit and Net Loss (as defined in Exhibit M of the Correspondence) applicable with respect to Commercialization of Products (but, for clarity, not any costs of Development) of Products in the U.S.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "No later than the Initiation of the first Registrational Clinical Trial for the first Product, Sanofi and RevMed shall enter into a profit/loss share agreement (the \"Profit/Loss Share Agreement\") pursuant to which the Parties shall equally share the Net Profit and Net Loss (as defined in Exhibit M of the Correspondence) applicable with respect to Commercialization of Products (but, for clarity, not any costs of Development) of Products in the U.S.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Subject to the other terms of this Section 9.3, during the Royalty Term, Sanofi shall make quarterly royalty payments to RevMed on aggregate Net Sales of each Product sold outside the United States during a Calendar Year at the applicable royalty rates as set forth below. For clarity, royalties shall only be payable once on any sale of Product under this Agreement.\n\nAggregate Net Sales of each Product outside the United States during a Calendar Year Royalty Rate Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year less than or equal to $[***] [***]% Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year greater than $[***] and less than or equal to $[***] [***]% Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year greater than $[***] and less than $[***] [***]% Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year greater than $[***] [***]% 45",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Subject to the other terms of this Section 9.3, during the Royalty Term, Sanofi shall make quarterly royalty payments to RevMed on aggregate Net Sales of each Product sold outside the United States during a Calendar Year at the applicable royalty rates as set forth below. For clarity, royalties shall only be payable once on any sale of Product under this Agreement.\n\nAggregate Net Sales of each Product outside the United States during a Calendar Year Royalty Rate Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year less than or equal to $[***] [***]% Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year greater than $[***] and less than or equal to $[***] [***]% Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year greater than $[***] and less than $[***] [***]% Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year greater than $[***] [***]% 45",
      "page_number": 2,
      "words": [
        {
          "text": "1.8 \"Applicable Law\"' means (a) any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution",
          "bbox": [
            388.0,
            294.0,
            3034.0,
            336.0
          ],
          "confidence": 0.9909149408340454
        },
        {
          "text": "or promulgation (including written governmental interpretations thereof, the guidance related thereto), (b) any judicial, governmental or administrative",
          "bbox": [
            275.0,
            347.0,
            2982.0,
            393.0
          ],
          "confidence": 0.9954527020454407
        },
        {
          "text": "order, judgment, decree or ruling by any Governmental Authority, or (c) any license, franchise, permit or similar right granted under any of the foregoing.",
          "bbox": [
            275.0,
            404.0,
            3016.0,
            448.0
          ],
          "confidence": 0.9922866225242615
        },
        {
          "text": "or any similar provision having the force or effect of law, in each case (a), (b) and (c) that may be in effect from time to time and as applicable to the",
          "bbox": [
            277.0,
            459.0,
            2918.0,
            501.0
          ],
          "confidence": 0.9928944706916809
        },
        {
          "text": "subject matter and the Persons at issue..",
          "bbox": [
            281.0,
            515.0,
            993.0,
            552.0
          ],
          "confidence": 0.9842612743377686
        },
        {
          "text": "1.9 \"Business Day\" means a day other than a Saturday or Sunday or a day on which banking institutions in San Francisco, California or in Paris,",
          "bbox": [
            388.0,
            618.0,
            3003.0,
            663.0
          ],
          "confidence": 0.9810460209846497
        },
        {
          "text": "France are permitted or required to be closed..",
          "bbox": [
            274.0,
            672.0,
            1091.0,
            718.0
          ],
          "confidence": 0.9813092947006226
        },
        {
          "text": "1.10 \"Calendar Quarter\" means each successive period of three calendar months commencing on January 1, April 1, July 1 and October 1, except.",
          "bbox": [
            388.0,
            784.0,
            3027.0,
            824.0
          ],
          "confidence": 0.987139105796814
        },
        {
          "text": "that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1,",
          "bbox": [
            277.0,
            837.0,
            2992.0,
            881.0
          ],
          "confidence": 0.9976634979248047
        },
        {
          "text": "April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term.",
          "bbox": [
            279.0,
            894.0,
            2409.0,
            936.0
          ],
          "confidence": 0.994002103805542
        },
        {
          "text": "1.11 \"Calendar Year' means each successive period of 12 calendar months commencing on January 1 and ending on December 31, except that the",
          "bbox": [
            386.0,
            998.0,
            3029.0,
            1043.0
          ],
          "confidence": 0.9929906725883484
        },
        {
          "text": "first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last",
          "bbox": [
            279.0,
            1058.0,
            3018.0,
            1095.0
          ],
          "confidence": 0.994539201259613
        },
        {
          "text": "Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.",
          "bbox": [
            275.0,
            1107.0,
            2568.0,
            1153.0
          ],
          "confidence": 0.9875234961509705
        },
        {
          "text": "1.12 \"Change of Control' means with respect to a Party (a) any sale, exchange, transfer, or issuance to or acquisition in one transaction or a series",
          "bbox": [
            388.0,
            1217.0,
            3038.0,
            1261.0
          ],
          "confidence": 0.9865206480026245
        },
        {
          "text": "of related transactions by one or more Third Parties of units and/or shares of equity (as applicable) representing 50% or more of the aggregate ordinary",
          "bbox": [
            275.0,
            1272.0,
            3000.0,
            1318.0
          ],
          "confidence": 0.9949914216995239
        },
        {
          "text": "voting power entitled to vote for the election of directors or managers represented by the issued and outstanding units of equity of such Party (or any",
          "bbox": [
            275.0,
            1327.0,
            2987.0,
            1372.0
          ],
          "confidence": 0.9923064112663269
        },
        {
          "text": "Affiliate that directly or indirectly controls such Party (such Affiliate, the \"Parent')), whether such sale, exchange, transfer, issuance or acquisition is",
          "bbox": [
            277.0,
            1380.0,
            2969.0,
            1425.0
          ],
          "confidence": 0.9908210635185242
        },
        {
          "text": "made directly or indirectly, by merger or otherwise, or beneficially or of record (collectively, a \"Stock Sale'); (b) a merger or consolidation under.",
          "bbox": [
            277.0,
            1440.0,
            2871.0,
            1476.0
          ],
          "confidence": 0.9874856472015381
        },
        {
          "text": "Applicable Law of such Party or a Parent with a Third Party, other than a merger or consolidation in which the units and/or shares of equity of such Party",
          "bbox": [
            279.0,
            1489.0,
            3036.0,
            1535.0
          ],
          "confidence": 0.9958277940750122
        },
        {
          "text": "or Parent outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or are exchanged for units and/or",
          "bbox": [
            279.0,
            1550.0,
            2980.0,
            1586.0
          ],
          "confidence": 0.9851700663566589
        },
        {
          "text": "shares of equity which represent, immediately following such merger or consolidation, 50% or more of the aggregate ordinary voting power of such units.",
          "bbox": [
            277.0,
            1601.0,
            3034.0,
            1643.0
          ],
          "confidence": 0.9877539873123169
        },
        {
          "text": "and/or shares of equity of the surviving or resulting entity or a parent entity of such surviving or resulting entity, whether direct or indirect (collectively, a.",
          "bbox": [
            277.0,
            1656.0,
            3049.0,
            1698.0
          ],
          "confidence": 0.994670569896698
        },
        {
          "text": "\"Merger'); (c) a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of such Party or a Parent to one or more",
          "bbox": [
            275.0,
            1707.0,
            3031.0,
            1752.0
          ],
          "confidence": 0.9951062798500061
        },
        {
          "text": "Third Parties in one transaction or a series of related transactions (collectively, the \"Asset Transfer\"). Notwithstanding the foregoing, a purchase of",
          "bbox": [
            275.0,
            1762.0,
            2956.0,
            1805.0
          ],
          "confidence": 0.9914079904556274
        },
        {
          "text": "shares in a Stock Sale by one or more Third Parties in a bona fide financing transaction the primary purpose of which is to raise working capital for",
          "bbox": [
            275.0,
            1816.0,
            2915.0,
            1860.0
          ],
          "confidence": 0.9903939366340637
        },
        {
          "text": "RevMed or to acquire assets from a Third Party (in either case including one or more public offerings) shall not constitute a Change of Control even if",
          "bbox": [
            276.0,
            1873.0,
            2982.0,
            1915.0
          ],
          "confidence": 0.9920164942741394
        },
        {
          "text": "such Third Parties collectively negotiate or receive their rights as security holders in such financing transaction(s), except that such exemption shall not",
          "bbox": [
            277.0,
            1930.0,
            3014.0,
            1966.0
          ],
          "confidence": 0.9951461553573608
        },
        {
          "text": "apply with respect to any Change of Control that would result in any Major Biopharmaceutical Company having more than 50% of the aggregate ordinary",
          "bbox": [
            275.0,
            1981.0,
            3045.0,
            2027.0
          ],
          "confidence": 0.9956365823745728
        },
        {
          "text": "voting power in RevMed or its Parent. The Parent of a Party for purposes of this Section 1.12 shall not include any.",
          "bbox": [
            277.0,
            2037.0,
            2340.0,
            2080.0
          ],
          "confidence": 0.9871761798858643
        },
        {
          "text": "3",
          "bbox": [
            1653.0,
            2092.0,
            1678.0,
            2123.0
          ],
          "confidence": 0.9931035041809082
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9971198439598083
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "If Net Sales of the applicable Product in a country in a Calendar Quarter following the Launch Quarter for such country are:\n\nA. lower than or equal to [***]%, but more than [***]%, of Base Net Sales of the applicable Product in such country, then the Applicable Reduction Percentage shall be [***]%; or\n\nB. lower than or equal to [***]% of Base Net Sales of the applicable Product in such country, then the Applicable Reduction Percentage shall be [***]%.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "If Net Sales of the applicable Product in a country in a Calendar Quarter following the Launch Quarter for such country are:\n\nA. lower than or equal to [***]%, but more than [***]%, of Base Net Sales of the applicable Product in such country, then the Applicable Reduction Percentage shall be [***]%; or\n\nB. lower than or equal to [***]% of Base Net Sales of the applicable Product in such country, then the Applicable Reduction Percentage shall be [***]%.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "In any country in which there is no Valid Claim and no Regulatory Exclusivity for such Product, at the time of sale of such Product in such country during the applicable Royalty Term, Sanofi's obligation to pay royalties under Section 9.3(a) on Net Sales of such Product in such country shall be reduced to [***]% of the rates otherwise payable under such section.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "In any country in which there is no Valid Claim and no Regulatory Exclusivity for such Product, at the time of sale of such Product in such country during the applicable Royalty Term, Sanofi's obligation to pay royalties under Section 9.3(a) on Net Sales of such Product in such country shall be reduced to [***]% of the rates otherwise payable under such section.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "If during the Royalty Term for a Product in a country, one or more Generic Products of such Product are sold in such country, and during any Calendar Quarter following the Calendar Quarter in which such Generic Product(s) are first sold in such country (the \"Launch Quarter\") Net Sales of such Product in such country during any Calendar Quarter following the Launch Quarter are less than the Designated Percentage (as defined below) of average Net Sales occurring during the [***] immediately preceding the Launch Quarter (such average Net Sales during such Calendar Quarters, the \"Base Net Sales\"), then the royalty rates provided in Section 9.3(a) for such Product shall be reduced in such country by the \"Applicable Reduction Percentage\" set forth below for such Calendar Quarter and for all future Calendar Quarters, unless and until the Generic Product is no longer sold or the Net Sales increase above the Base Net Sales in a Calendar Quarter.",
      "page_number": 2,
      "words": [
        {
          "text": "1.8 \"Applicable Law\"' means (a) any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution",
          "bbox": [
            388.0,
            294.0,
            3034.0,
            336.0
          ],
          "confidence": 0.9909149408340454
        },
        {
          "text": "or promulgation (including written governmental interpretations thereof, the guidance related thereto), (b) any judicial, governmental or administrative",
          "bbox": [
            275.0,
            347.0,
            2982.0,
            393.0
          ],
          "confidence": 0.9954527020454407
        },
        {
          "text": "order, judgment, decree or ruling by any Governmental Authority, or (c) any license, franchise, permit or similar right granted under any of the foregoing.",
          "bbox": [
            275.0,
            404.0,
            3016.0,
            448.0
          ],
          "confidence": 0.9922866225242615
        },
        {
          "text": "or any similar provision having the force or effect of law, in each case (a), (b) and (c) that may be in effect from time to time and as applicable to the",
          "bbox": [
            277.0,
            459.0,
            2918.0,
            501.0
          ],
          "confidence": 0.9928944706916809
        },
        {
          "text": "subject matter and the Persons at issue..",
          "bbox": [
            281.0,
            515.0,
            993.0,
            552.0
          ],
          "confidence": 0.9842612743377686
        },
        {
          "text": "1.9 \"Business Day\" means a day other than a Saturday or Sunday or a day on which banking institutions in San Francisco, California or in Paris,",
          "bbox": [
            388.0,
            618.0,
            3003.0,
            663.0
          ],
          "confidence": 0.9810460209846497
        },
        {
          "text": "France are permitted or required to be closed..",
          "bbox": [
            274.0,
            672.0,
            1091.0,
            718.0
          ],
          "confidence": 0.9813092947006226
        },
        {
          "text": "1.10 \"Calendar Quarter\" means each successive period of three calendar months commencing on January 1, April 1, July 1 and October 1, except.",
          "bbox": [
            388.0,
            784.0,
            3027.0,
            824.0
          ],
          "confidence": 0.987139105796814
        },
        {
          "text": "that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1,",
          "bbox": [
            277.0,
            837.0,
            2992.0,
            881.0
          ],
          "confidence": 0.9976634979248047
        },
        {
          "text": "April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term.",
          "bbox": [
            279.0,
            894.0,
            2409.0,
            936.0
          ],
          "confidence": 0.994002103805542
        },
        {
          "text": "1.11 \"Calendar Year' means each successive period of 12 calendar months commencing on January 1 and ending on December 31, except that the",
          "bbox": [
            386.0,
            998.0,
            3029.0,
            1043.0
          ],
          "confidence": 0.9929906725883484
        },
        {
          "text": "first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last",
          "bbox": [
            279.0,
            1058.0,
            3018.0,
            1095.0
          ],
          "confidence": 0.994539201259613
        },
        {
          "text": "Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.",
          "bbox": [
            275.0,
            1107.0,
            2568.0,
            1153.0
          ],
          "confidence": 0.9875234961509705
        },
        {
          "text": "1.12 \"Change of Control' means with respect to a Party (a) any sale, exchange, transfer, or issuance to or acquisition in one transaction or a series",
          "bbox": [
            388.0,
            1217.0,
            3038.0,
            1261.0
          ],
          "confidence": 0.9865206480026245
        },
        {
          "text": "of related transactions by one or more Third Parties of units and/or shares of equity (as applicable) representing 50% or more of the aggregate ordinary",
          "bbox": [
            275.0,
            1272.0,
            3000.0,
            1318.0
          ],
          "confidence": 0.9949914216995239
        },
        {
          "text": "voting power entitled to vote for the election of directors or managers represented by the issued and outstanding units of equity of such Party (or any",
          "bbox": [
            275.0,
            1327.0,
            2987.0,
            1372.0
          ],
          "confidence": 0.9923064112663269
        },
        {
          "text": "Affiliate that directly or indirectly controls such Party (such Affiliate, the \"Parent')), whether such sale, exchange, transfer, issuance or acquisition is",
          "bbox": [
            277.0,
            1380.0,
            2969.0,
            1425.0
          ],
          "confidence": 0.9908210635185242
        },
        {
          "text": "made directly or indirectly, by merger or otherwise, or beneficially or of record (collectively, a \"Stock Sale'); (b) a merger or consolidation under.",
          "bbox": [
            277.0,
            1440.0,
            2871.0,
            1476.0
          ],
          "confidence": 0.9874856472015381
        },
        {
          "text": "Applicable Law of such Party or a Parent with a Third Party, other than a merger or consolidation in which the units and/or shares of equity of such Party",
          "bbox": [
            279.0,
            1489.0,
            3036.0,
            1535.0
          ],
          "confidence": 0.9958277940750122
        },
        {
          "text": "or Parent outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or are exchanged for units and/or",
          "bbox": [
            279.0,
            1550.0,
            2980.0,
            1586.0
          ],
          "confidence": 0.9851700663566589
        },
        {
          "text": "shares of equity which represent, immediately following such merger or consolidation, 50% or more of the aggregate ordinary voting power of such units.",
          "bbox": [
            277.0,
            1601.0,
            3034.0,
            1643.0
          ],
          "confidence": 0.9877539873123169
        },
        {
          "text": "and/or shares of equity of the surviving or resulting entity or a parent entity of such surviving or resulting entity, whether direct or indirect (collectively, a.",
          "bbox": [
            277.0,
            1656.0,
            3049.0,
            1698.0
          ],
          "confidence": 0.994670569896698
        },
        {
          "text": "\"Merger'); (c) a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of such Party or a Parent to one or more",
          "bbox": [
            275.0,
            1707.0,
            3031.0,
            1752.0
          ],
          "confidence": 0.9951062798500061
        },
        {
          "text": "Third Parties in one transaction or a series of related transactions (collectively, the \"Asset Transfer\"). Notwithstanding the foregoing, a purchase of",
          "bbox": [
            275.0,
            1762.0,
            2956.0,
            1805.0
          ],
          "confidence": 0.9914079904556274
        },
        {
          "text": "shares in a Stock Sale by one or more Third Parties in a bona fide financing transaction the primary purpose of which is to raise working capital for",
          "bbox": [
            275.0,
            1816.0,
            2915.0,
            1860.0
          ],
          "confidence": 0.9903939366340637
        },
        {
          "text": "RevMed or to acquire assets from a Third Party (in either case including one or more public offerings) shall not constitute a Change of Control even if",
          "bbox": [
            276.0,
            1873.0,
            2982.0,
            1915.0
          ],
          "confidence": 0.9920164942741394
        },
        {
          "text": "such Third Parties collectively negotiate or receive their rights as security holders in such financing transaction(s), except that such exemption shall not",
          "bbox": [
            277.0,
            1930.0,
            3014.0,
            1966.0
          ],
          "confidence": 0.9951461553573608
        },
        {
          "text": "apply with respect to any Change of Control that would result in any Major Biopharmaceutical Company having more than 50% of the aggregate ordinary",
          "bbox": [
            275.0,
            1981.0,
            3045.0,
            2027.0
          ],
          "confidence": 0.9956365823745728
        },
        {
          "text": "voting power in RevMed or its Parent. The Parent of a Party for purposes of this Section 1.12 shall not include any.",
          "bbox": [
            277.0,
            2037.0,
            2340.0,
            2080.0
          ],
          "confidence": 0.9871761798858643
        },
        {
          "text": "3",
          "bbox": [
            1653.0,
            2092.0,
            1678.0,
            2123.0
          ],
          "confidence": 0.9931035041809082
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9971198439598083
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "If during the Royalty Term for a Product in a country, one or more Generic Products of such Product are sold in such country, and during any Calendar Quarter following the Calendar Quarter in which such Generic Product(s) are first sold in such country (the \"Launch Quarter\") Net Sales of such Product in such country during any Calendar Quarter following the Launch Quarter are less than the Designated Percentage (as defined below) of average Net Sales occurring during the [***] immediately preceding the Launch Quarter (such average Net Sales during such Calendar Quarters, the \"Base Net Sales\"), then the royalty rates provided in Section 9.3(a) for such Product shall be reduced in such country by the \"Applicable Reduction Percentage\" set forth below for such Calendar Quarter and for all future Calendar Quarters, unless and until the Generic Product is no longer sold or the Net Sales increase above the Base Net Sales in a Calendar Quarter.",
      "page_number": 3,
      "words": [
        {
          "text": "Excluded Investor, provided that the applicable Stock Sale, Merger or Asset Transfer does not result in any Major Biopharmaceutical Company having.",
          "bbox": [
            275.0,
            292.0,
            2991.0,
            338.0
          ],
          "confidence": 0.9902107119560242
        },
        {
          "text": "more than 50% of the aggregate ordinary voting power in, or control over all or substantially all of the assets of, RevMed or its Parent or any surviving or.",
          "bbox": [
            276.0,
            349.0,
            3047.0,
            393.0
          ],
          "confidence": 0.9834804534912109
        },
        {
          "text": "resulting entity or a parent entity of such surviving or resulting entity.",
          "bbox": [
            277.0,
            407.0,
            1535.0,
            444.0
          ],
          "confidence": 0.9948831796646118
        },
        {
          "text": "1.13 \"Clinical Trial\" means any clinical investigation conducted on human subjects, as that term is defined in FDA regulations at 21 C.F.R. s",
          "bbox": [
            390.0,
            512.0,
            2947.0,
            554.0
          ],
          "confidence": 0.9906536340713501
        },
        {
          "text": "312.3. Without limiting the foregoing, Clinical Trial includes any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, Phase 4 Study or.",
          "bbox": [
            275.0,
            563.0,
            2911.0,
            610.0
          ],
          "confidence": 0.9943299889564514
        },
        {
          "text": "variations of the foregoing.",
          "bbox": [
            275.0,
            616.0,
            769.0,
            667.0
          ],
          "confidence": 0.9962665438652039
        },
        {
          "text": "1.14 \"Collaboration' means the collaboration of the Parties with respect to the Research, Development, Manufacture and Commercialization of",
          "bbox": [
            388.0,
            729.0,
            2980.0,
            771.0
          ],
          "confidence": 0.9932978749275208
        },
        {
          "text": "Products in the Field, as and to the extent set forth in this Agreement and the Ancillary Agreements.",
          "bbox": [
            277.0,
            784.0,
            2086.0,
            824.0
          ],
          "confidence": 0.9921536445617676
        },
        {
          "text": "1.15 \"Combination Product' means any pharmaceutical preparation in final form containing a SHP2 Inhibitor in combination with one or more.",
          "bbox": [
            388.0,
            890.0,
            2951.0,
            936.0
          ],
          "confidence": 0.9906741976737976
        },
        {
          "text": "additional active ingredients, for sale by prescription or any other method either as a fixed dose or unit or as separate doses or units in a single package.",
          "bbox": [
            275.0,
            945.0,
            3011.0,
            990.0
          ],
          "confidence": 0.991058349609375
        },
        {
          "text": "1.16 \"Commercialization'' means the marketing, promotion, sale or distribution of Products (or Companion Diagnostics for Products in",
          "bbox": [
            386.0,
            1053.0,
            2840.0,
            1098.0
          ],
          "confidence": 0.9773974418640137
        },
        {
          "text": "accordance with this Agreement) in the Field, including: (a) commercial activities conducted in preparation for commercial launch of a Product; (b).",
          "bbox": [
            276.0,
            1111.0,
            2904.0,
            1153.0
          ],
          "confidence": 0.9890528321266174
        },
        {
          "text": "strategic marketing, sale force detailing, advertising, medical education and liaison; (c) any Phase 4 Studies, except Required Phase 4 Studies; and (d) all",
          "bbox": [
            275.0,
            1166.0,
            3012.0,
            1206.0
          ],
          "confidence": 0.9897938370704651
        },
        {
          "text": "customer support, product distribution, invoicing and other sales activities. \"Commercialize\" and \"Commercializing' have a correlative meaning.",
          "bbox": [
            272.0,
            1215.0,
            2925.0,
            1266.0
          ],
          "confidence": 0.987463116645813
        },
        {
          "text": "1.17 \"Commercially Reasonable Efforts\"' means: (a) with respect to Sanofi, [***], consistent with [***] that [***], taking into account [***],",
          "bbox": [
            390.0,
            1327.0,
            2951.0,
            1371.0
          ],
          "confidence": 0.9838429689407349
        },
        {
          "text": "including [***] and (b) with respect to RevMed, [***], consistent with [***] that [***], taking into account [***], including [***].",
          "bbox": [
            276.0,
            1380.0,
            2648.0,
            1429.0
          ],
          "confidence": 0.998206377029419
        },
        {
          "text": "1.18 \"Committee\" means the JSC, JRDC, JCC, JPC or any subcommittee established under Article II, as applicable",
          "bbox": [
            388.0,
            1491.0,
            2454.0,
            1533.0
          ],
          "confidence": 0.993331789970398
        },
        {
          "text": "1.19 \"Companion Diagnostic' means, with respect to a Product, (a) a companion diagnostic approved by the applicable Regulatory Authority that.",
          "bbox": [
            388.0,
            1597.0,
            3043.0,
            1643.0
          ],
          "confidence": 0.9911240935325623
        },
        {
          "text": "provides information essential to the safe and effective use of such Product or is otherwise necessary for the Regulatory Approval of such Product, or",
          "bbox": [
            279.0,
            1656.0,
            2996.0,
            1698.0
          ],
          "confidence": 0.9951832890510559
        },
        {
          "text": "(b) a complementary diagnostic that provides information helpful to the safe and effective use of such Product but is not a companion diagnostic referred",
          "bbox": [
            279.0,
            1709.0,
            3045.0,
            1751.0
          ],
          "confidence": 0.9933711290359497
        },
        {
          "text": "to in the foregoing clause (a)..",
          "bbox": [
            276.0,
            1765.0,
            807.0,
            1807.0
          ],
          "confidence": 0.9675626754760742
        },
        {
          "text": "1.20 \"Competing Product' means, other than a Product, any pharmaceutical preparation [***] that satisfies the criteria [***], alone or in",
          "bbox": [
            388.0,
            1871.0,
            2860.0,
            1915.0
          ],
          "confidence": 0.9884178042411804
        },
        {
          "text": "combination with one or more additional active ingredients, for sale by prescription or any other method.",
          "bbox": [
            275.0,
            1924.0,
            2162.0,
            1970.0
          ],
          "confidence": 0.9894286394119263
        },
        {
          "text": "4",
          "bbox": [
            1649.0,
            1981.0,
            1680.0,
            2017.0
          ],
          "confidence": 0.9507763981819153
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9970430731773376
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "If Sanofi enters into an agreement with a Third Party in order to obtain a license or other right to a Third Party Right that is reasonably necessary to manufacture, use or sell a Product (or the SHP2 Inhibitor contained therein) in a country pursuant to Section 10.7, Sanofi shall be entitled to deduct from the royalties payable under Section 9.3(a) with respect to such Product in such country in a particular Calendar Quarter [***] paid by Sanofi to such Third Party in respect of such agreement for such Calendar Quarter, in each case to the extent reasonably allocable to such Third Party Right and such Product and country; provided that in no event shall the royalties payable for such Product and country in any Calendar Quarter be reduced to less than [***]% of the amount otherwise due under Section 9.3(a) (the \"Royalty Floor\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "If Sanofi enters into an agreement with a Third Party in order to obtain a license or other right to a Third Party Right that is reasonably necessary to manufacture, use or sell a Product (or the SHP2 Inhibitor contained therein) in a country pursuant to Section 10.7, Sanofi shall be entitled to deduct from the royalties payable under Section 9.3(a) with respect to such Product in such country in a particular Calendar Quarter [***] paid by Sanofi to such Third Party in respect of such agreement for such Calendar Quarter, in each case to the extent reasonably allocable to such Third Party Right and such Product and country; provided that in no event shall the royalties payable for such Product and country in any Calendar Quarter be reduced to less than [***]% of the amount otherwise due under Section 9.3(a) (the \"Royalty Floor\").",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Volume Restriction_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one partyâs use of the product/services exceeds certain threshold?",
      "answer_text": "Furthermore, Sanofi shall within [***] after the effective date of such termination, transfer to RevMed all files and documents relating to the prosecution, defense or enforcement of the RevMed Licensed Patents or Joint Program Patents and provide reasonable assistance for a period not to exceed [***] following the effective date of termination, up to a total of [***], in the transfer of the prosecution, defense and enforcement responsibilities to RevMed, including by executing any documents reasonable necessary therefor.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Volume Restriction_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one partyâs use of the product/services exceeds certain threshold?",
      "answer_text": "Furthermore, Sanofi shall within [***] after the effective date of such termination, transfer to RevMed all files and documents relating to the prosecution, defense or enforcement of the RevMed Licensed Patents or Joint Program Patents and provide reasonable assistance for a period not to exceed [***] following the effective date of termination, up to a total of [***], in the transfer of the prosecution, defense and enforcement responsibilities to RevMed, including by executing any documents reasonable necessary therefor.",
      "page_number": 2,
      "words": [
        {
          "text": "1.8 \"Applicable Law\"' means (a) any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution",
          "bbox": [
            388.0,
            294.0,
            3034.0,
            336.0
          ],
          "confidence": 0.9909149408340454
        },
        {
          "text": "or promulgation (including written governmental interpretations thereof, the guidance related thereto), (b) any judicial, governmental or administrative",
          "bbox": [
            275.0,
            347.0,
            2982.0,
            393.0
          ],
          "confidence": 0.9954527020454407
        },
        {
          "text": "order, judgment, decree or ruling by any Governmental Authority, or (c) any license, franchise, permit or similar right granted under any of the foregoing.",
          "bbox": [
            275.0,
            404.0,
            3016.0,
            448.0
          ],
          "confidence": 0.9922866225242615
        },
        {
          "text": "or any similar provision having the force or effect of law, in each case (a), (b) and (c) that may be in effect from time to time and as applicable to the",
          "bbox": [
            277.0,
            459.0,
            2918.0,
            501.0
          ],
          "confidence": 0.9928944706916809
        },
        {
          "text": "subject matter and the Persons at issue..",
          "bbox": [
            281.0,
            515.0,
            993.0,
            552.0
          ],
          "confidence": 0.9842612743377686
        },
        {
          "text": "1.9 \"Business Day\" means a day other than a Saturday or Sunday or a day on which banking institutions in San Francisco, California or in Paris,",
          "bbox": [
            388.0,
            618.0,
            3003.0,
            663.0
          ],
          "confidence": 0.9810460209846497
        },
        {
          "text": "France are permitted or required to be closed..",
          "bbox": [
            274.0,
            672.0,
            1091.0,
            718.0
          ],
          "confidence": 0.9813092947006226
        },
        {
          "text": "1.10 \"Calendar Quarter\" means each successive period of three calendar months commencing on January 1, April 1, July 1 and October 1, except.",
          "bbox": [
            388.0,
            784.0,
            3027.0,
            824.0
          ],
          "confidence": 0.987139105796814
        },
        {
          "text": "that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1,",
          "bbox": [
            277.0,
            837.0,
            2992.0,
            881.0
          ],
          "confidence": 0.9976634979248047
        },
        {
          "text": "April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term.",
          "bbox": [
            279.0,
            894.0,
            2409.0,
            936.0
          ],
          "confidence": 0.994002103805542
        },
        {
          "text": "1.11 \"Calendar Year' means each successive period of 12 calendar months commencing on January 1 and ending on December 31, except that the",
          "bbox": [
            386.0,
            998.0,
            3029.0,
            1043.0
          ],
          "confidence": 0.9929906725883484
        },
        {
          "text": "first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last",
          "bbox": [
            279.0,
            1058.0,
            3018.0,
            1095.0
          ],
          "confidence": 0.994539201259613
        },
        {
          "text": "Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.",
          "bbox": [
            275.0,
            1107.0,
            2568.0,
            1153.0
          ],
          "confidence": 0.9875234961509705
        },
        {
          "text": "1.12 \"Change of Control' means with respect to a Party (a) any sale, exchange, transfer, or issuance to or acquisition in one transaction or a series",
          "bbox": [
            388.0,
            1217.0,
            3038.0,
            1261.0
          ],
          "confidence": 0.9865206480026245
        },
        {
          "text": "of related transactions by one or more Third Parties of units and/or shares of equity (as applicable) representing 50% or more of the aggregate ordinary",
          "bbox": [
            275.0,
            1272.0,
            3000.0,
            1318.0
          ],
          "confidence": 0.9949914216995239
        },
        {
          "text": "voting power entitled to vote for the election of directors or managers represented by the issued and outstanding units of equity of such Party (or any",
          "bbox": [
            275.0,
            1327.0,
            2987.0,
            1372.0
          ],
          "confidence": 0.9923064112663269
        },
        {
          "text": "Affiliate that directly or indirectly controls such Party (such Affiliate, the \"Parent')), whether such sale, exchange, transfer, issuance or acquisition is",
          "bbox": [
            277.0,
            1380.0,
            2969.0,
            1425.0
          ],
          "confidence": 0.9908210635185242
        },
        {
          "text": "made directly or indirectly, by merger or otherwise, or beneficially or of record (collectively, a \"Stock Sale'); (b) a merger or consolidation under.",
          "bbox": [
            277.0,
            1440.0,
            2871.0,
            1476.0
          ],
          "confidence": 0.9874856472015381
        },
        {
          "text": "Applicable Law of such Party or a Parent with a Third Party, other than a merger or consolidation in which the units and/or shares of equity of such Party",
          "bbox": [
            279.0,
            1489.0,
            3036.0,
            1535.0
          ],
          "confidence": 0.9958277940750122
        },
        {
          "text": "or Parent outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or are exchanged for units and/or",
          "bbox": [
            279.0,
            1550.0,
            2980.0,
            1586.0
          ],
          "confidence": 0.9851700663566589
        },
        {
          "text": "shares of equity which represent, immediately following such merger or consolidation, 50% or more of the aggregate ordinary voting power of such units.",
          "bbox": [
            277.0,
            1601.0,
            3034.0,
            1643.0
          ],
          "confidence": 0.9877539873123169
        },
        {
          "text": "and/or shares of equity of the surviving or resulting entity or a parent entity of such surviving or resulting entity, whether direct or indirect (collectively, a.",
          "bbox": [
            277.0,
            1656.0,
            3049.0,
            1698.0
          ],
          "confidence": 0.994670569896698
        },
        {
          "text": "\"Merger'); (c) a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of such Party or a Parent to one or more",
          "bbox": [
            275.0,
            1707.0,
            3031.0,
            1752.0
          ],
          "confidence": 0.9951062798500061
        },
        {
          "text": "Third Parties in one transaction or a series of related transactions (collectively, the \"Asset Transfer\"). Notwithstanding the foregoing, a purchase of",
          "bbox": [
            275.0,
            1762.0,
            2956.0,
            1805.0
          ],
          "confidence": 0.9914079904556274
        },
        {
          "text": "shares in a Stock Sale by one or more Third Parties in a bona fide financing transaction the primary purpose of which is to raise working capital for",
          "bbox": [
            275.0,
            1816.0,
            2915.0,
            1860.0
          ],
          "confidence": 0.9903939366340637
        },
        {
          "text": "RevMed or to acquire assets from a Third Party (in either case including one or more public offerings) shall not constitute a Change of Control even if",
          "bbox": [
            276.0,
            1873.0,
            2982.0,
            1915.0
          ],
          "confidence": 0.9920164942741394
        },
        {
          "text": "such Third Parties collectively negotiate or receive their rights as security holders in such financing transaction(s), except that such exemption shall not",
          "bbox": [
            277.0,
            1930.0,
            3014.0,
            1966.0
          ],
          "confidence": 0.9951461553573608
        },
        {
          "text": "apply with respect to any Change of Control that would result in any Major Biopharmaceutical Company having more than 50% of the aggregate ordinary",
          "bbox": [
            275.0,
            1981.0,
            3045.0,
            2027.0
          ],
          "confidence": 0.9956365823745728
        },
        {
          "text": "voting power in RevMed or its Parent. The Parent of a Party for purposes of this Section 1.12 shall not include any.",
          "bbox": [
            277.0,
            2037.0,
            2340.0,
            2080.0
          ],
          "confidence": 0.9871761798858643
        },
        {
          "text": "3",
          "bbox": [
            1653.0,
            2092.0,
            1678.0,
            2123.0
          ],
          "confidence": 0.9931035041809082
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9971198439598083
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Volume Restriction_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one partyâs use of the product/services exceeds certain threshold?",
      "answer_text": "At RevMed's reasonable request, for a period not to exceed [***] following the effective date of termination, Sanofi shall provide RevMed with assistance up to a total of [***] with any inquiries and correspondence with Regulatory Authorities relating to any such Termination Product.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Volume Restriction_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one partyâs use of the product/services exceeds certain threshold?",
      "answer_text": "At RevMed's reasonable request, for a period not to exceed [***] following the effective date of termination, Sanofi shall provide RevMed with assistance up to a total of [***] with any inquiries and correspondence with Regulatory Authorities relating to any such Termination Product.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Volume Restriction_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one partyâs use of the product/services exceeds certain threshold?",
      "answer_text": "Sanofi shall, at RevMed's request, for a period not to exceed [***] following the effective date of termination, provide reasonable technical assistance up to a total of [***] and, to the extent not already provided to RevMed, transfer copies of (including when available, in electronic format) all Sanofi Sole Program Know-How to RevMed or its designee, including without limitation: [***], in each case to the extent such materials are exclusively related to the Termination Product.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Volume Restriction_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one partyâs use of the product/services exceeds certain threshold?",
      "answer_text": "Sanofi shall, at RevMed's request, for a period not to exceed [***] following the effective date of termination, provide reasonable technical assistance up to a total of [***] and, to the extent not already provided to RevMed, transfer copies of (including when available, in electronic format) all Sanofi Sole Program Know-How to RevMed or its designee, including without limitation: [***], in each case to the extent such materials are exclusively related to the Termination Product.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Once RevMed has completed conducting all Clinical Trials for a Product assigned to it under the Development Plan for such Product, RevMed agrees to assign, and hereby does assign, to Sanofi all of its rights, title and interests in and to all Regulatory Approvals (including INDs and NDAs) for such Product.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Once RevMed has completed conducting all Clinical Trials for a Product assigned to it under the Development Plan for such Product, RevMed agrees to assign, and hereby does assign, to Sanofi all of its rights, title and interests in and to all Regulatory Approvals (including INDs and NDAs) for such Product.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Ip Ownership Assignment_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Sanofi shall transfer and assign, and shall ensure that its Affiliates transfer and assign, to RevMed, at no cost to RevMed, all Product Marks exclusively relating to any Termination Product, provided that such Product Marks do not contain the business entity names of Sanofi or its Affiliates or variations thereof, except as may otherwise be required by Applicable Law during a transition period to avoid any interruptions in supply of Termination Product to patients. I",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Sanofi shall transfer and assign, and shall ensure that its Affiliates transfer and assign, to RevMed, at no cost to RevMed, all Product Marks exclusively relating to any Termination Product, provided that such Product Marks do not contain the business entity names of Sanofi or its Affiliates or variations thereof, except as may otherwise be required by Applicable Law during a transition period to avoid any interruptions in supply of Termination Product to patients. I",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Joint Ip Ownership_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "Subject to the other terms and conditions of this Agreement (including the licenses and other rights granted under this Agreement or any Ancillary Agreement), each Party shall have the right to exploit, including license, the Joint Program Technology, without a duty of accounting or any obligation to seek consent from the other Party to exploit such Joint Program Technology.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Joint Ip Ownership_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "Subject to the other terms and conditions of this Agreement (including the licenses and other rights granted under this Agreement or any Ancillary Agreement), each Party shall have the right to exploit, including license, the Joint Program Technology, without a duty of accounting or any obligation to seek consent from the other Party to exploit such Joint Program Technology.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Sanofi hereby grants to RevMed a non-exclusive, royalty-free sublicense (which shall only be further sub-licensable (a) to RevMed's Subsidiaries, (b) to the Permitted Contractors or Researchers, and (c) solely with Sanofi's prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, to Third Parties who are not Permitted Contractors or Researchers) under the rights exclusively licensed to Sanofi pursuant to Section 3.1, solely to the extent necessary for RevMed to perform its obligations under this Agreement and the Ancillary Agreements.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Sanofi hereby grants to RevMed a non-exclusive, royalty-free sublicense (which shall only be further sub-licensable (a) to RevMed's Subsidiaries, (b) to the Permitted Contractors or Researchers, and (c) solely with Sanofi's prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, to Third Parties who are not Permitted Contractors or Researchers) under the rights exclusively licensed to Sanofi pursuant to Section 3.1, solely to the extent necessary for RevMed to perform its obligations under this Agreement and the Ancillary Agreements.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Sanofi shall have rights to use, at no additional cost, any RevMed Study Data in its performance of its obligations and exercise of its rights under the Collaboration except in connection with filing of MAAs for the Indication and Product Treatment Regimen that were the subject of such RevMed Study.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Sanofi shall have rights to use, at no additional cost, any RevMed Study Data in its performance of its obligations and exercise of its rights under the Collaboration except in connection with filing of MAAs for the Indication and Product Treatment Regimen that were the subject of such RevMed Study.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "To the extent necessary to effect the foregoing in a country other than the United States, each Party grants to the other Party a nonexclusive, irrevocable, perpetual, fully-paid, worldwide license, with the right to grant sublicenses, under the granting Party's interest in Joint Program Technology, for any and all purposes, provided that RevMed's interest therein shall be subject to the other terms and conditions of this Agreement, including the exclusive licenses granted herein (during the Term) and all payment obligations.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "To the extent necessary to effect the foregoing in a country other than the United States, each Party grants to the other Party a nonexclusive, irrevocable, perpetual, fully-paid, worldwide license, with the right to grant sublicenses, under the granting Party's interest in Joint Program Technology, for any and all purposes, provided that RevMed's interest therein shall be subject to the other terms and conditions of this Agreement, including the exclusive licenses granted herein (during the Term) and all payment obligations.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_12",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Upon expiration of this Agreement, the licenses granted to Sanofi under Section 3.1 will become fully paid up, royalty free, perpetual and irrevocable.",
      "page_number": 12,
      "words": [
        {
          "text": "1.83 \"Program Inventions\"' means any Know-How conceived, reduced to practice, developed, made or otherwise generated by or on behalf of a",
          "bbox": [
            388.0,
            294.0,
            3000.0,
            336.0
          ],
          "confidence": 0.9933552145957947
        },
        {
          "text": "Party or its Affiliates or Sublicensees in connection with the Research, Development, Manufacture or Commercialization of SHP2 Inhibitors or Products",
          "bbox": [
            277.0,
            349.0,
            3005.0,
            391.0
          ],
          "confidence": 0.9935019016265869
        },
        {
          "text": "under this Agreement or any Ancillary Agreement, including all rights, title and interest in and to the intellectual property rights therein.",
          "bbox": [
            277.0,
            404.0,
            2726.0,
            446.0
          ],
          "confidence": 0.998060941696167
        },
        {
          "text": "1.84 \"Publication\"' means any release of information, including any presentation, which information (a) has not been disclosed pursuant to Section",
          "bbox": [
            386.0,
            510.0,
            3052.0,
            556.0
          ],
          "confidence": 0.9919794201850891
        },
        {
          "text": "11.3 or (b) has not previously been publicly disclosed.",
          "bbox": [
            279.0,
            565.0,
            1254.0,
            610.0
          ],
          "confidence": 0.9891147017478943
        },
        {
          "text": "1.85 \"Registrational Clinical Trial' means a Clinical Trial of a Product designed to be adequate to achieve Regulatory Approval of such Product",
          "bbox": [
            386.0,
            672.0,
            3027.0,
            718.0
          ],
          "confidence": 0.9938868880271912
        },
        {
          "text": "and that would satisfy the requirements of 21 C.F.R 312.21(c), as amended, or corresponding foreign regulations, regardless of whether such trial is",
          "bbox": [
            277.0,
            729.0,
            2922.0,
            773.0
          ],
          "confidence": 0.9970631003379822
        },
        {
          "text": "referred to as a \"phase 2b clinical trial\", \"phase 2b/3 clinical trial'' or \"phase 3 clinical trial', but excluding, for clarity, any investigator-initiated Clinical",
          "bbox": [
            276.0,
            784.0,
            2976.0,
            826.0
          ],
          "confidence": 0.9791915416717529
        },
        {
          "text": "Trials.",
          "bbox": [
            273.0,
            833.0,
            388.0,
            881.0
          ],
          "confidence": 0.9392772316932678
        },
        {
          "text": "1.86 \"Regulatory Approval' means, with respect to a country or jurisdiction, any and all approvals (including Marketing Approvals), licenses,",
          "bbox": [
            390.0,
            948.0,
            2960.0,
            990.0
          ],
          "confidence": 0.9960633516311646
        },
        {
          "text": "registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a Product in such country or jurisdiction,",
          "bbox": [
            276.0,
            1003.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9957284331321716
        },
        {
          "text": "including, where applicable, (a) pricing or reimbursement approval in such country or jurisdiction, (b) pre- and post-approval marketing authorizations",
          "bbox": [
            277.0,
            1058.0,
            2978.0,
            1100.0
          ],
          "confidence": 0.9925866723060608
        },
        {
          "text": "(including any prerequisite Manufacturing approval or authorization related thereto) and (c) labeling approval.",
          "bbox": [
            279.0,
            1111.0,
            2269.0,
            1155.0
          ],
          "confidence": 0.9997178316116333
        },
        {
          "text": "1.87 \"Regulatory Authority\" means any applicable Governmental Authority involved in the granting Regulatory Approvals for the Products or",
          "bbox": [
            390.0,
            1221.0,
            2991.0,
            1263.0
          ],
          "confidence": 0.9873211979866028
        },
        {
          "text": "otherwise exercising authority with respect to biopharmaceutical products in the applicable country or jurisdiction, including the FDA, the EMA, the",
          "bbox": [
            277.0,
            1275.0,
            2956.0,
            1318.0
          ],
          "confidence": 0.9921106100082397
        },
        {
          "text": "PMDA and any corresponding national or regional regulatory authorities.",
          "bbox": [
            275.0,
            1327.0,
            1604.0,
            1371.0
          ],
          "confidence": 0.9983550310134888
        },
        {
          "text": "1.88 \"Regulatory Exclusivity\" means any rights or protections which are recognized, afforded or granted by the FDA or any other Regulatory",
          "bbox": [
            388.0,
            1434.0,
            2954.0,
            1482.0
          ],
          "confidence": 0.9879338145256042
        },
        {
          "text": "Authority in any country or region of the Territory pursuant to Applicable Laws of such country or region, in association with the marketing",
          "bbox": [
            277.0,
            1489.0,
            2813.0,
            1537.0
          ],
          "confidence": 0.9942042827606201
        },
        {
          "text": "authorization of the Product, providing the Product[***] a period of marketing exclusivity, during which a Regulatory Authority recognizing, affording or",
          "bbox": [
            277.0,
            1546.0,
            3038.0,
            1588.0
          ],
          "confidence": 0.9974392056465149
        },
        {
          "text": "granting such marketing exclusivity will refrain from either reviewing or approving a marketing authorization application or similar regulatory submission,",
          "bbox": [
            279.0,
            1601.0,
            3029.0,
            1645.0
          ],
          "confidence": 0.9985029697418213
        },
        {
          "text": "1.89 \"Regulatory Materials' all (a) applications (including all INDs), registrations, licenses, authorizations and approvals (including MAAs and",
          "bbox": [
            388.0,
            1762.0,
            3005.0,
            1805.0
          ],
          "confidence": 0.9920071363449097
        },
        {
          "text": "Regulatory Approvals), (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact",
          "bbox": [
            275.0,
            1816.0,
            2963.0,
            1862.0
          ],
          "confidence": 0.9905570149421692
        },
        {
          "text": "reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event",
          "bbox": [
            274.0,
            1871.0,
            2996.0,
            1917.0
          ],
          "confidence": 0.990648627281189
        },
        {
          "text": "files and complaint files, (c) clinical and other data contained, referenced or otherwise relied upon in any of the foregoing, and (d) for clarity, any drug",
          "bbox": [
            275.0,
            1924.0,
            2965.0,
            1970.0
          ],
          "confidence": 0.9951865077018738
        },
        {
          "text": "master file.",
          "bbox": [
            274.0,
            1983.0,
            468.0,
            2021.0
          ],
          "confidence": 0.9816405773162842
        },
        {
          "text": "1.90 \"Required Phase 4 Studies\"' means any Phase 4 Studies that are required by the applicable Regulatory Authority to be conducted as a.",
          "bbox": [
            390.0,
            2090.0,
            2920.0,
            2133.0
          ],
          "confidence": 0.9853315353393555
        },
        {
          "text": "condition for Regulatory Approval, including Regulatory Approval for a label expansion, whether or not also required for pricing or reimbursement.",
          "bbox": [
            277.0,
            2143.0,
            2925.0,
            2187.0
          ],
          "confidence": 0.9941840767860413
        },
        {
          "text": "approval.",
          "bbox": [
            275.0,
            2196.0,
            450.0,
            2244.0
          ],
          "confidence": 0.9473364353179932
        },
        {
          "text": "13",
          "bbox": [
            1638.0,
            2249.0,
            1691.0,
            2295.0
          ],
          "confidence": 0.9965152740478516
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9849861860275269
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "License Grants.\n\n1. RevMed License to SHP2 Inhibitors. Sanofi shall, effective upon any such termination of this Agreement, and hereby does, grant to RevMed [***], under all [***], and [***], to [***]. Notwithstanding the foregoing, [***] shall not include [***], and [***] shall include [***] (to the extent [***]).\n\n2. RevMed License to Practice Certain Combinations. Sanofi shall, effective upon any such termination of this Agreement, and hereby does, grant to RevMed [***], under [***], and [***] (but excluding [***]). For the avoidance of doubt, [***] licensed under this Section 12.3(c)(ii)(A)(2) do not [***]. 60\n\nSource: REVOLUTION MEDICINES, INC., S-1, 1/17/2020\n\n\n\n\n\n3. Sanofi License to Practice Certain Combinations. [***] RevMed shall, effective upon any such termination of this Agreement, and hereby does, grant to Sanofi [***], under [***], and [***]. For the avoidance of doubt, [***] licensed under this Section 12.3(c)(ii)(A)(3) do not [***]. If Sanofi [***], Sanofi shall so notify RevMed in writing, and [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "License Grants.\n\n1. RevMed License to SHP2 Inhibitors. Sanofi shall, effective upon any such termination of this Agreement, and hereby does, grant to RevMed [***], under all [***], and [***], to [***]. Notwithstanding the foregoing, [***] shall not include [***], and [***] shall include [***] (to the extent [***]).\n\n2. RevMed License to Practice Certain Combinations. Sanofi shall, effective upon any such termination of this Agreement, and hereby does, grant to RevMed [***], under [***], and [***] (but excluding [***]). For the avoidance of doubt, [***] licensed under this Section 12.3(c)(ii)(A)(2) do not [***]. 60\n\nSource: REVOLUTION MEDICINES, INC., S-1, 1/17/2020\n\n\n\n\n\n3. Sanofi License to Practice Certain Combinations. [***] RevMed shall, effective upon any such termination of this Agreement, and hereby does, grant to Sanofi [***], under [***], and [***]. For the avoidance of doubt, [***] licensed under this Section 12.3(c)(ii)(A)(3) do not [***]. If Sanofi [***], Sanofi shall so notify RevMed in writing, and [***].",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "All licenses and other rights granted to Sanofi under the RevMed Licensed Technology under this Agreement shall terminate (except as necessary to permit Sanofi to perform its surviving obligations under this Article XII) and all rights thereunder shall revert to RevMed; provided, however, RevMed shall, effective upon any such termination of this Agreement, and hereby does, grant to Sanofi a non- exclusive, worldwide license, with the right to grant sublicenses to contractors and otherwise only with RevMed's prior written consent, under each (1) RevMed Program Invention and (2) [***]. F",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "All licenses and other rights granted to Sanofi under the RevMed Licensed Technology under this Agreement shall terminate (except as necessary to permit Sanofi to perform its surviving obligations under this Article XII) and all rights thereunder shall revert to RevMed; provided, however, RevMed shall, effective upon any such termination of this Agreement, and hereby does, grant to Sanofi a non- exclusive, worldwide license, with the right to grant sublicenses to contractors and otherwise only with RevMed's prior written consent, under each (1) RevMed Program Invention and (2) [***]. F",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an exclusive (even as to RevMed and its Affiliates), royalty-bearing license (which shall be sub-licensable solely as provided in Section 3.4) under the RevMed Licensed Technology, to Research, Develop, Manufacture, use, sell, offer for sale, import and otherwise Commercialize and exploit Products (including, for clarity, any Companion Diagnostics with respect to such Products) in the Field in the Licensed Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an exclusive (even as to RevMed and its Affiliates), royalty-bearing license (which shall be sub-licensable solely as provided in Section 3.4) under the RevMed Licensed Technology, to Research, Develop, Manufacture, use, sell, offer for sale, import and otherwise Commercialize and exploit Products (including, for clarity, any Companion Diagnostics with respect to such Products) in the Field in the Licensed Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Non-Transferable License_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "Except as part of a transaction permitted under this Section 15.2, in no event shall RevMed assign or transfer, or agree to assign or transfer to any Third Party, any or all of the RevMed Licensed Patents without the consent of Sanofi, not be unreasonably withheld or conditioned.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Non-Transferable License_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "Except as part of a transaction permitted under this Section 15.2, in no event shall RevMed assign or transfer, or agree to assign or transfer to any Third Party, any or all of the RevMed Licensed Patents without the consent of Sanofi, not be unreasonably withheld or conditioned.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Affiliate License-Licensee_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Sanofi hereby grants to RevMed a non-exclusive, royalty-free sublicense (which shall only be further sub-licensable (a) to RevMed's Subsidiaries, (b) to the Permitted Contractors or Researchers, and (c) solely with Sanofi's prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, to Third Parties who are not Permitted Contractors or Researchers) under the rights exclusively licensed to Sanofi pursuant to Section 3.1, solely to the extent necessary for RevMed to perform its obligations under this Agreement and the Ancillary Agreements.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Affiliate License-Licensee_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Sanofi hereby grants to RevMed a non-exclusive, royalty-free sublicense (which shall only be further sub-licensable (a) to RevMed's Subsidiaries, (b) to the Permitted Contractors or Researchers, and (c) solely with Sanofi's prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, to Third Parties who are not Permitted Contractors or Researchers) under the rights exclusively licensed to Sanofi pursuant to Section 3.1, solely to the extent necessary for RevMed to perform its obligations under this Agreement and the Ancillary Agreements.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Affiliate License-Licensee_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Sanofi shall have the right, in its sole discretion, to appoint its Affiliates, and Sanofi and its Affiliates shall have the right, in its sole discretion, to appoint any other Persons, in the Licensed Territory to distribute, market, and sell the Products (with or without packaging rights), in circumstances where the Person purchases its requirements of Products from Sanofi or its Affiliates but does not otherwise make any royalty or other payment to Sanofi or its Affiliates with respect to its intellectual property or other proprietary rights.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Affiliate License-Licensee_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Sanofi shall have the right, in its sole discretion, to appoint its Affiliates, and Sanofi and its Affiliates shall have the right, in its sole discretion, to appoint any other Persons, in the Licensed Territory to distribute, market, and sell the Products (with or without packaging rights), in circumstances where the Person purchases its requirements of Products from Sanofi or its Affiliates but does not otherwise make any royalty or other payment to Sanofi or its Affiliates with respect to its intellectual property or other proprietary rights.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Irrevocable Or Perpetual License_12",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "Upon expiration of this Agreement, the licenses granted to Sanofi under Section 3.1 will become fully paid up, royalty free, perpetual and irrevocable.",
      "page_number": 12,
      "words": [
        {
          "text": "1.83 \"Program Inventions\"' means any Know-How conceived, reduced to practice, developed, made or otherwise generated by or on behalf of a",
          "bbox": [
            388.0,
            294.0,
            3000.0,
            336.0
          ],
          "confidence": 0.9933552145957947
        },
        {
          "text": "Party or its Affiliates or Sublicensees in connection with the Research, Development, Manufacture or Commercialization of SHP2 Inhibitors or Products",
          "bbox": [
            277.0,
            349.0,
            3005.0,
            391.0
          ],
          "confidence": 0.9935019016265869
        },
        {
          "text": "under this Agreement or any Ancillary Agreement, including all rights, title and interest in and to the intellectual property rights therein.",
          "bbox": [
            277.0,
            404.0,
            2726.0,
            446.0
          ],
          "confidence": 0.998060941696167
        },
        {
          "text": "1.84 \"Publication\"' means any release of information, including any presentation, which information (a) has not been disclosed pursuant to Section",
          "bbox": [
            386.0,
            510.0,
            3052.0,
            556.0
          ],
          "confidence": 0.9919794201850891
        },
        {
          "text": "11.3 or (b) has not previously been publicly disclosed.",
          "bbox": [
            279.0,
            565.0,
            1254.0,
            610.0
          ],
          "confidence": 0.9891147017478943
        },
        {
          "text": "1.85 \"Registrational Clinical Trial' means a Clinical Trial of a Product designed to be adequate to achieve Regulatory Approval of such Product",
          "bbox": [
            386.0,
            672.0,
            3027.0,
            718.0
          ],
          "confidence": 0.9938868880271912
        },
        {
          "text": "and that would satisfy the requirements of 21 C.F.R 312.21(c), as amended, or corresponding foreign regulations, regardless of whether such trial is",
          "bbox": [
            277.0,
            729.0,
            2922.0,
            773.0
          ],
          "confidence": 0.9970631003379822
        },
        {
          "text": "referred to as a \"phase 2b clinical trial\", \"phase 2b/3 clinical trial'' or \"phase 3 clinical trial', but excluding, for clarity, any investigator-initiated Clinical",
          "bbox": [
            276.0,
            784.0,
            2976.0,
            826.0
          ],
          "confidence": 0.9791915416717529
        },
        {
          "text": "Trials.",
          "bbox": [
            273.0,
            833.0,
            388.0,
            881.0
          ],
          "confidence": 0.9392772316932678
        },
        {
          "text": "1.86 \"Regulatory Approval' means, with respect to a country or jurisdiction, any and all approvals (including Marketing Approvals), licenses,",
          "bbox": [
            390.0,
            948.0,
            2960.0,
            990.0
          ],
          "confidence": 0.9960633516311646
        },
        {
          "text": "registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a Product in such country or jurisdiction,",
          "bbox": [
            276.0,
            1003.0,
            3029.0,
            1045.0
          ],
          "confidence": 0.9957284331321716
        },
        {
          "text": "including, where applicable, (a) pricing or reimbursement approval in such country or jurisdiction, (b) pre- and post-approval marketing authorizations",
          "bbox": [
            277.0,
            1058.0,
            2978.0,
            1100.0
          ],
          "confidence": 0.9925866723060608
        },
        {
          "text": "(including any prerequisite Manufacturing approval or authorization related thereto) and (c) labeling approval.",
          "bbox": [
            279.0,
            1111.0,
            2269.0,
            1155.0
          ],
          "confidence": 0.9997178316116333
        },
        {
          "text": "1.87 \"Regulatory Authority\" means any applicable Governmental Authority involved in the granting Regulatory Approvals for the Products or",
          "bbox": [
            390.0,
            1221.0,
            2991.0,
            1263.0
          ],
          "confidence": 0.9873211979866028
        },
        {
          "text": "otherwise exercising authority with respect to biopharmaceutical products in the applicable country or jurisdiction, including the FDA, the EMA, the",
          "bbox": [
            277.0,
            1275.0,
            2956.0,
            1318.0
          ],
          "confidence": 0.9921106100082397
        },
        {
          "text": "PMDA and any corresponding national or regional regulatory authorities.",
          "bbox": [
            275.0,
            1327.0,
            1604.0,
            1371.0
          ],
          "confidence": 0.9983550310134888
        },
        {
          "text": "1.88 \"Regulatory Exclusivity\" means any rights or protections which are recognized, afforded or granted by the FDA or any other Regulatory",
          "bbox": [
            388.0,
            1434.0,
            2954.0,
            1482.0
          ],
          "confidence": 0.9879338145256042
        },
        {
          "text": "Authority in any country or region of the Territory pursuant to Applicable Laws of such country or region, in association with the marketing",
          "bbox": [
            277.0,
            1489.0,
            2813.0,
            1537.0
          ],
          "confidence": 0.9942042827606201
        },
        {
          "text": "authorization of the Product, providing the Product[***] a period of marketing exclusivity, during which a Regulatory Authority recognizing, affording or",
          "bbox": [
            277.0,
            1546.0,
            3038.0,
            1588.0
          ],
          "confidence": 0.9974392056465149
        },
        {
          "text": "granting such marketing exclusivity will refrain from either reviewing or approving a marketing authorization application or similar regulatory submission,",
          "bbox": [
            279.0,
            1601.0,
            3029.0,
            1645.0
          ],
          "confidence": 0.9985029697418213
        },
        {
          "text": "1.89 \"Regulatory Materials' all (a) applications (including all INDs), registrations, licenses, authorizations and approvals (including MAAs and",
          "bbox": [
            388.0,
            1762.0,
            3005.0,
            1805.0
          ],
          "confidence": 0.9920071363449097
        },
        {
          "text": "Regulatory Approvals), (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact",
          "bbox": [
            275.0,
            1816.0,
            2963.0,
            1862.0
          ],
          "confidence": 0.9905570149421692
        },
        {
          "text": "reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event",
          "bbox": [
            274.0,
            1871.0,
            2996.0,
            1917.0
          ],
          "confidence": 0.990648627281189
        },
        {
          "text": "files and complaint files, (c) clinical and other data contained, referenced or otherwise relied upon in any of the foregoing, and (d) for clarity, any drug",
          "bbox": [
            275.0,
            1924.0,
            2965.0,
            1970.0
          ],
          "confidence": 0.9951865077018738
        },
        {
          "text": "master file.",
          "bbox": [
            274.0,
            1983.0,
            468.0,
            2021.0
          ],
          "confidence": 0.9816405773162842
        },
        {
          "text": "1.90 \"Required Phase 4 Studies\"' means any Phase 4 Studies that are required by the applicable Regulatory Authority to be conducted as a.",
          "bbox": [
            390.0,
            2090.0,
            2920.0,
            2133.0
          ],
          "confidence": 0.9853315353393555
        },
        {
          "text": "condition for Regulatory Approval, including Regulatory Approval for a label expansion, whether or not also required for pricing or reimbursement.",
          "bbox": [
            277.0,
            2143.0,
            2925.0,
            2187.0
          ],
          "confidence": 0.9941840767860413
        },
        {
          "text": "approval.",
          "bbox": [
            275.0,
            2196.0,
            450.0,
            2244.0
          ],
          "confidence": 0.9473364353179932
        },
        {
          "text": "13",
          "bbox": [
            1638.0,
            2249.0,
            1691.0,
            2295.0
          ],
          "confidence": 0.9965152740478516
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9849861860275269
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Irrevocable Or Perpetual License_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "To the extent necessary to effect the foregoing in a country other than the United States, each Party grants to the other Party a nonexclusive, irrevocable, perpetual, fully-paid, worldwide license, with the right to grant sublicenses, under the granting Party's interest in Joint Program Technology, for any and all purposes, provided that RevMed's interest therein shall be subject to the other terms and conditions of this Agreement, including the exclusive licenses granted herein (during the Term) and all payment obligations.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Irrevocable Or Perpetual License_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "To the extent necessary to effect the foregoing in a country other than the United States, each Party grants to the other Party a nonexclusive, irrevocable, perpetual, fully-paid, worldwide license, with the right to grant sublicenses, under the granting Party's interest in Joint Program Technology, for any and all purposes, provided that RevMed's interest therein shall be subject to the other terms and conditions of this Agreement, including the exclusive licenses granted herein (during the Term) and all payment obligations.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Within [***] after the effective date of such termination for Termination Products for which Regulatory Approval has been obtained prior to the effective date of such termination or [***] for other Termination Products (or as promptly as practical thereafter, if such period is not practical under Applicable Law), Sanofi shall transfer and assign to RevMed all Regulatory Approvals relating to such Termination Products, and, to the extent not previously provided to RevMed, transfer other Regulatory Materials including data from preclinical, non-clinical and clinical studies conducted by or on behalf of Sanofi, its Affiliates or Sublicensees on such Termination Products and all pharmacovigilance data (including all adverse event databases) on such Termination Products",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Within [***] after the effective date of such termination for Termination Products for which Regulatory Approval has been obtained prior to the effective date of such termination or [***] for other Termination Products (or as promptly as practical thereafter, if such period is not practical under Applicable Law), Sanofi shall transfer and assign to RevMed all Regulatory Approvals relating to such Termination Products, and, to the extent not previously provided to RevMed, transfer other Regulatory Materials including data from preclinical, non-clinical and clinical studies conducted by or on behalf of Sanofi, its Affiliates or Sublicensees on such Termination Products and all pharmacovigilance data (including all adverse event databases) on such Termination Products",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities, for at least [***] after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities, for at least [***] after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Sanofi shall, at RevMed's request, for a period not to exceed [***] following the effective date of termination, provide reasonable technical assistance up to a total of [***] and, to the extent not already provided to RevMed, transfer copies of (including when available, in electronic format) all Sanofi Sole Program Know-How to RevMed or its designee, including without limitation: [***], in each case to the extent such materials are exclusively related to the Termination Product.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Sanofi shall, at RevMed's request, for a period not to exceed [***] following the effective date of termination, provide reasonable technical assistance up to a total of [***] and, to the extent not already provided to RevMed, transfer copies of (including when available, in electronic format) all Sanofi Sole Program Know-How to RevMed or its designee, including without limitation: [***], in each case to the extent such materials are exclusively related to the Termination Product.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "With regard to Termination Products in countries for which the licenses to Sanofi are terminating, Sanofi shall provide the following transitional assistance, with costs allocated as set forth below",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "RevMed shall pay Sanofi such royalties until the earlier of (x) expiration of the Post-Termination Royalty Term therefor and (y) a Change of Control of Sanofi.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "If at the time of such termination, Sanofi or its Affiliates are Commercializing a particular Termination Product, then, at RevMed's request, the Parties shall negotiate in good faith a transition services agreement to cover detailing and promotion of such Termination Product (in the same manner and no more extensive than the then-current detailing and promotional efforts of Sanofi) by Sanofi or its Affiliate or contract sales force pursuant to a transition plan agreed by the Parties for a period not to exceed [***], and RevMed shall pay Sanofi a commercially reasonable amount to conduct such activities (which amount would include a commercially reasonable per-detail rate).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "If at the time of such termination, Sanofi or its Affiliates are Commercializing a particular Termination Product, then, at RevMed's request, the Parties shall negotiate in good faith a transition services agreement to cover detailing and promotion of such Termination Product (in the same manner and no more extensive than the then-current detailing and promotional efforts of Sanofi) by Sanofi or its Affiliate or contract sales force pursuant to a transition plan agreed by the Parties for a period not to exceed [***], and RevMed shall pay Sanofi a commercially reasonable amount to conduct such activities (which amount would include a commercially reasonable per-detail rate).",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "If this Agreement is terminated in its entirety or with respect to one or more Products, other than by RevMed pursuant to Section 12.2(b) (Termination for Material Breach) or 12.2(c) (Termination for Insolvency), RevMed shall pay to Sanofi on a Product-by-Product basis royalties on sales of terminated Products (such Products, which for the purpose of clarity shall not include any Non-SHP2 Product, hereinafter referred to as \"Termination Products\"), calculated based on worldwide Net Sales (as such term is applied mutatis mutandis to RevMed and including sales in the U.S.) by RevMed and its Affiliates and Sublicensees of such Termination Products as follows: [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "If this Agreement is terminated in its entirety or with respect to one or more Products, other than by RevMed pursuant to Section 12.2(b) (Termination for Material Breach) or 12.2(c) (Termination for Insolvency), RevMed shall pay to Sanofi on a Product-by-Product basis royalties on sales of terminated Products (such Products, which for the purpose of clarity shall not include any Non-SHP2 Product, hereinafter referred to as \"Termination Products\"), calculated based on worldwide Net Sales (as such term is applied mutatis mutandis to RevMed and including sales in the U.S.) by RevMed and its Affiliates and Sublicensees of such Termination Products as follows: [***].",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Sanofi shall transfer and assign, and shall ensure that its Affiliates transfer and assign, to RevMed, at no cost to RevMed, all Product Marks exclusively relating to any Termination Product, provided that such Product Marks do not contain the business entity names of Sanofi or its Affiliates or variations thereof, except as may otherwise be required by Applicable Law during a transition period to avoid any interruptions in supply of Termination Product to patients. I",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Sanofi shall transfer and assign, and shall ensure that its Affiliates transfer and assign, to RevMed, at no cost to RevMed, all Product Marks exclusively relating to any Termination Product, provided that such Product Marks do not contain the business entity names of Sanofi or its Affiliates or variations thereof, except as may otherwise be required by Applicable Law during a transition period to avoid any interruptions in supply of Termination Product to patients. I",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the case of a termination of this Agreement, Sanofi (with respect to the Termination Products in the Licensed Territory), shall be entitled, for a period of [***] after termination, to (i) complete Manufacture of work-in-progress, and (ii) continue conducting Commercialization activities being conducted by Sanofi hereunder as of such termination (if applicable, with respect to the terminated country(ies)), to the extent related to Termination Product in Sanofi's inventory as of such termination (or added to such inventory as a result of the completion described in clause (i)), provided that Sanofi fulfills its payment obligations under this Agreement in connection with such inventory sell-off, provided further that the payment of royalties to RevMed and the sharing of Net Profits and Net Losses under the Profit/Loss Share Agreement shall continue to apply during the sell-off period.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the case of a termination of this Agreement, Sanofi (with respect to the Termination Products in the Licensed Territory), shall be entitled, for a period of [***] after termination, to (i) complete Manufacture of work-in-progress, and (ii) continue conducting Commercialization activities being conducted by Sanofi hereunder as of such termination (if applicable, with respect to the terminated country(ies)), to the extent related to Termination Product in Sanofi's inventory as of such termination (or added to such inventory as a result of the completion described in clause (i)), provided that Sanofi fulfills its payment obligations under this Agreement in connection with such inventory sell-off, provided further that the payment of royalties to RevMed and the sharing of Net Profits and Net Losses under the Profit/Loss Share Agreement shall continue to apply during the sell-off period.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In addition to the foregoing, Sanofi shall use reasonable efforts with respect to those activities for which it is responsible hereunder to cooperate with RevMed to achieve an orderly transition of the Development, Manufacturing and Commercialization of Termination Products from Sanofi or its applicable Affiliate to RevMed.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In addition to the foregoing, Sanofi shall use reasonable efforts with respect to those activities for which it is responsible hereunder to cooperate with RevMed to achieve an orderly transition of the Development, Manufacturing and Commercialization of Termination Products from Sanofi or its applicable Affiliate to RevMed.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Furthermore, Sanofi shall within [***] after the effective date of such termination, transfer to RevMed all files and documents relating to the prosecution, defense or enforcement of the RevMed Licensed Patents or Joint Program Patents and provide reasonable assistance for a period not to exceed [***] following the effective date of termination, up to a total of [***], in the transfer of the prosecution, defense and enforcement responsibilities to RevMed, including by executing any documents reasonable necessary therefor.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Furthermore, Sanofi shall within [***] after the effective date of such termination, transfer to RevMed all files and documents relating to the prosecution, defense or enforcement of the RevMed Licensed Patents or Joint Program Patents and provide reasonable assistance for a period not to exceed [***] following the effective date of termination, up to a total of [***], in the transfer of the prosecution, defense and enforcement responsibilities to RevMed, including by executing any documents reasonable necessary therefor.",
      "page_number": 2,
      "words": [
        {
          "text": "1.8 \"Applicable Law\"' means (a) any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution",
          "bbox": [
            388.0,
            294.0,
            3034.0,
            336.0
          ],
          "confidence": 0.9909149408340454
        },
        {
          "text": "or promulgation (including written governmental interpretations thereof, the guidance related thereto), (b) any judicial, governmental or administrative",
          "bbox": [
            275.0,
            347.0,
            2982.0,
            393.0
          ],
          "confidence": 0.9954527020454407
        },
        {
          "text": "order, judgment, decree or ruling by any Governmental Authority, or (c) any license, franchise, permit or similar right granted under any of the foregoing.",
          "bbox": [
            275.0,
            404.0,
            3016.0,
            448.0
          ],
          "confidence": 0.9922866225242615
        },
        {
          "text": "or any similar provision having the force or effect of law, in each case (a), (b) and (c) that may be in effect from time to time and as applicable to the",
          "bbox": [
            277.0,
            459.0,
            2918.0,
            501.0
          ],
          "confidence": 0.9928944706916809
        },
        {
          "text": "subject matter and the Persons at issue..",
          "bbox": [
            281.0,
            515.0,
            993.0,
            552.0
          ],
          "confidence": 0.9842612743377686
        },
        {
          "text": "1.9 \"Business Day\" means a day other than a Saturday or Sunday or a day on which banking institutions in San Francisco, California or in Paris,",
          "bbox": [
            388.0,
            618.0,
            3003.0,
            663.0
          ],
          "confidence": 0.9810460209846497
        },
        {
          "text": "France are permitted or required to be closed..",
          "bbox": [
            274.0,
            672.0,
            1091.0,
            718.0
          ],
          "confidence": 0.9813092947006226
        },
        {
          "text": "1.10 \"Calendar Quarter\" means each successive period of three calendar months commencing on January 1, April 1, July 1 and October 1, except.",
          "bbox": [
            388.0,
            784.0,
            3027.0,
            824.0
          ],
          "confidence": 0.987139105796814
        },
        {
          "text": "that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1,",
          "bbox": [
            277.0,
            837.0,
            2992.0,
            881.0
          ],
          "confidence": 0.9976634979248047
        },
        {
          "text": "April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term.",
          "bbox": [
            279.0,
            894.0,
            2409.0,
            936.0
          ],
          "confidence": 0.994002103805542
        },
        {
          "text": "1.11 \"Calendar Year' means each successive period of 12 calendar months commencing on January 1 and ending on December 31, except that the",
          "bbox": [
            386.0,
            998.0,
            3029.0,
            1043.0
          ],
          "confidence": 0.9929906725883484
        },
        {
          "text": "first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last",
          "bbox": [
            279.0,
            1058.0,
            3018.0,
            1095.0
          ],
          "confidence": 0.994539201259613
        },
        {
          "text": "Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.",
          "bbox": [
            275.0,
            1107.0,
            2568.0,
            1153.0
          ],
          "confidence": 0.9875234961509705
        },
        {
          "text": "1.12 \"Change of Control' means with respect to a Party (a) any sale, exchange, transfer, or issuance to or acquisition in one transaction or a series",
          "bbox": [
            388.0,
            1217.0,
            3038.0,
            1261.0
          ],
          "confidence": 0.9865206480026245
        },
        {
          "text": "of related transactions by one or more Third Parties of units and/or shares of equity (as applicable) representing 50% or more of the aggregate ordinary",
          "bbox": [
            275.0,
            1272.0,
            3000.0,
            1318.0
          ],
          "confidence": 0.9949914216995239
        },
        {
          "text": "voting power entitled to vote for the election of directors or managers represented by the issued and outstanding units of equity of such Party (or any",
          "bbox": [
            275.0,
            1327.0,
            2987.0,
            1372.0
          ],
          "confidence": 0.9923064112663269
        },
        {
          "text": "Affiliate that directly or indirectly controls such Party (such Affiliate, the \"Parent')), whether such sale, exchange, transfer, issuance or acquisition is",
          "bbox": [
            277.0,
            1380.0,
            2969.0,
            1425.0
          ],
          "confidence": 0.9908210635185242
        },
        {
          "text": "made directly or indirectly, by merger or otherwise, or beneficially or of record (collectively, a \"Stock Sale'); (b) a merger or consolidation under.",
          "bbox": [
            277.0,
            1440.0,
            2871.0,
            1476.0
          ],
          "confidence": 0.9874856472015381
        },
        {
          "text": "Applicable Law of such Party or a Parent with a Third Party, other than a merger or consolidation in which the units and/or shares of equity of such Party",
          "bbox": [
            279.0,
            1489.0,
            3036.0,
            1535.0
          ],
          "confidence": 0.9958277940750122
        },
        {
          "text": "or Parent outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or are exchanged for units and/or",
          "bbox": [
            279.0,
            1550.0,
            2980.0,
            1586.0
          ],
          "confidence": 0.9851700663566589
        },
        {
          "text": "shares of equity which represent, immediately following such merger or consolidation, 50% or more of the aggregate ordinary voting power of such units.",
          "bbox": [
            277.0,
            1601.0,
            3034.0,
            1643.0
          ],
          "confidence": 0.9877539873123169
        },
        {
          "text": "and/or shares of equity of the surviving or resulting entity or a parent entity of such surviving or resulting entity, whether direct or indirect (collectively, a.",
          "bbox": [
            277.0,
            1656.0,
            3049.0,
            1698.0
          ],
          "confidence": 0.994670569896698
        },
        {
          "text": "\"Merger'); (c) a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of such Party or a Parent to one or more",
          "bbox": [
            275.0,
            1707.0,
            3031.0,
            1752.0
          ],
          "confidence": 0.9951062798500061
        },
        {
          "text": "Third Parties in one transaction or a series of related transactions (collectively, the \"Asset Transfer\"). Notwithstanding the foregoing, a purchase of",
          "bbox": [
            275.0,
            1762.0,
            2956.0,
            1805.0
          ],
          "confidence": 0.9914079904556274
        },
        {
          "text": "shares in a Stock Sale by one or more Third Parties in a bona fide financing transaction the primary purpose of which is to raise working capital for",
          "bbox": [
            275.0,
            1816.0,
            2915.0,
            1860.0
          ],
          "confidence": 0.9903939366340637
        },
        {
          "text": "RevMed or to acquire assets from a Third Party (in either case including one or more public offerings) shall not constitute a Change of Control even if",
          "bbox": [
            276.0,
            1873.0,
            2982.0,
            1915.0
          ],
          "confidence": 0.9920164942741394
        },
        {
          "text": "such Third Parties collectively negotiate or receive their rights as security holders in such financing transaction(s), except that such exemption shall not",
          "bbox": [
            277.0,
            1930.0,
            3014.0,
            1966.0
          ],
          "confidence": 0.9951461553573608
        },
        {
          "text": "apply with respect to any Change of Control that would result in any Major Biopharmaceutical Company having more than 50% of the aggregate ordinary",
          "bbox": [
            275.0,
            1981.0,
            3045.0,
            2027.0
          ],
          "confidence": 0.9956365823745728
        },
        {
          "text": "voting power in RevMed or its Parent. The Parent of a Party for purposes of this Section 1.12 shall not include any.",
          "bbox": [
            277.0,
            2037.0,
            2340.0,
            2080.0
          ],
          "confidence": 0.9871761798858643
        },
        {
          "text": "3",
          "bbox": [
            1653.0,
            2092.0,
            1678.0,
            2123.0
          ],
          "confidence": 0.9931035041809082
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9971198439598083
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the case of a termination of this Agreement, Sanofi (with respect to the Termination Products in the Licensed Territory), shall be entitled, for a period of [***] after termination, to (i) complete Manufacture of work-in-progress, and (ii) continue conducting Commercialization activities being conducted by Sanofi hereunder as of such termination (if applicable, with respect to the terminated country(ies)), to the extent related to such Termination Product in Sanofi's inventory as of such termination (or added to such inventory as a result of the completion described in clause (i)), provided that Sanofi fulfills its payment obligations under this Agreement in connection with such inventory sell-off, provided further that the sharing of Net Profits and Net Losses under the Profit/Loss Share Agreement shall continue to apply during the sell-off period.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the case of a termination of this Agreement, Sanofi (with respect to the Termination Products in the Licensed Territory), shall be entitled, for a period of [***] after termination, to (i) complete Manufacture of work-in-progress, and (ii) continue conducting Commercialization activities being conducted by Sanofi hereunder as of such termination (if applicable, with respect to the terminated country(ies)), to the extent related to such Termination Product in Sanofi's inventory as of such termination (or added to such inventory as a result of the completion described in clause (i)), provided that Sanofi fulfills its payment obligations under this Agreement in connection with such inventory sell-off, provided further that the sharing of Net Profits and Net Losses under the Profit/Loss Share Agreement shall continue to apply during the sell-off period.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Within [***] of the effective date of such termination (or as promptly as practical thereafter, if such period is not practical under Applicable Law), [***], Sanofi shall transfer and assign to RevMed all Regulatory Approvals relating to Termination Products, and, to the extent not previously provided to RevMed, transfer other Regulatory Materials including data from preclinical, non-clinical and clinical studies conducted by or on behalf of Sanofi, its Affiliates or Sublicensees on any Termination Products and all pharmacovigilance data (including all adverse event databases) on any Termination Products.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Within [***] of the effective date of such termination (or as promptly as practical thereafter, if such period is not practical under Applicable Law), [***], Sanofi shall transfer and assign to RevMed all Regulatory Approvals relating to Termination Products, and, to the extent not previously provided to RevMed, transfer other Regulatory Materials including data from preclinical, non-clinical and clinical studies conducted by or on behalf of Sanofi, its Affiliates or Sublicensees on any Termination Products and all pharmacovigilance data (including all adverse event databases) on any Termination Products.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Upon termination of [***] by Sanofi pursuant to Section 12.2(a)(ii)B (Termination by Sanofi for Change of Control) in the case of an Acquiror of RevMed that is a Major Biopharmaceutical Company, RevMed, [***], will (1) make available to Sanofi copies of [***], (2) provide Sanofi with copies of [***], (3) provide Sanofi with all [***], and (4) otherwise provide Sanofi all reasonable assistance in [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Upon termination of [***] by Sanofi pursuant to Section 12.2(a)(ii)B (Termination by Sanofi for Change of Control) in the case of an Acquiror of RevMed that is a Major Biopharmaceutical Company, RevMed, [***], will (1) make available to Sanofi copies of [***], (2) provide Sanofi with copies of [***], (3) provide Sanofi with all [***], and (4) otherwise provide Sanofi all reasonable assistance in [***].",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "If at the time of such termination, Sanofi or its Affiliates are conducting any Clinical Trials (including Registrational Clinical Trials) of a Termination Product, then, at RevMed's election on a trial-by-trial basis, Sanofi shall cooperate, and shall ensure that its Affiliates cooperate, with RevMed to transfer the conduct of all such Clinical Trials to RevMed within [***] after the effective date of such transfer (to the extent practical in light of applicable regulatory and patient safety concerns) and RevMed shall assume any and all liability, and is liable, for such Clinical Trials conducted after the effective date of such termination (except to the extent Sanofi has an obligation of indemnification under Article XIV existing for a claim that arose prior to the effective date of such termination).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "If at the time of such termination, Sanofi or its Affiliates are conducting any Clinical Trials (including Registrational Clinical Trials) of a Termination Product, then, at RevMed's election on a trial-by-trial basis, Sanofi shall cooperate, and shall ensure that its Affiliates cooperate, with RevMed to transfer the conduct of all such Clinical Trials to RevMed within [***] after the effective date of such transfer (to the extent practical in light of applicable regulatory and patient safety concerns) and RevMed shall assume any and all liability, and is liable, for such Clinical Trials conducted after the effective date of such termination (except to the extent Sanofi has an obligation of indemnification under Article XIV existing for a claim that arose prior to the effective date of such termination).",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "At the end of the sell-off period set forth in Section 12.3(c)(iii), Sanofi shall transfer to RevMed any and all inventory of SHP2 Inhibitors and Termination Products (including all research materials, final product, bulk drug substance, intermediates, work-in-process, formulation materials, reference standards, drug product clinical reserve samples, packaged retention samples, and the like) then in the possession of Sanofi, its Affiliates or Sublicensees, and continue or have continued any ongoing stability studies pertaining to any materials so transferred to RevMed for a reasonable period of time until RevMed can assume responsibility for such activities",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "At the end of the sell-off period set forth in Section 12.3(c)(iii), Sanofi shall transfer to RevMed any and all inventory of SHP2 Inhibitors and Termination Products (including all research materials, final product, bulk drug substance, intermediates, work-in-process, formulation materials, reference standards, drug product clinical reserve samples, packaged retention samples, and the like) then in the possession of Sanofi, its Affiliates or Sublicensees, and continue or have continued any ongoing stability studies pertaining to any materials so transferred to RevMed for a reasonable period of time until RevMed can assume responsibility for such activities",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "At RevMed's reasonable request, for a period not to exceed [***] following the effective date of termination, Sanofi shall provide RevMed with assistance up to a total of [***] with any inquiries and correspondence with Regulatory Authorities relating to any such Termination Product.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "At RevMed's reasonable request, for a period not to exceed [***] following the effective date of termination, Sanofi shall provide RevMed with assistance up to a total of [***] with any inquiries and correspondence with Regulatory Authorities relating to any such Termination Product.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Upon any termination of this Agreement, RevMed shall pay to Sanofi any amounts owed to Third Parties under license agreements to which Sanofi is a party that grant Sanofi a license under such Third Party's Patent Rights or Know-How that is sublicensed to RevMed pursuant to Section 12.3(c)(ii)A, unless RevMed declines in writing to obtain such sublicense. \"Post-Termination Royalty Term\" means: (I) with respect to a particular country and a particular Termination Product that is the subject of the royalty obligations under Section 12.3(c)(ii)B(1), the period of time commencing upon the First Commercial Sale of such Termination Product in such country (by RevMed or its Affiliates or sublicensees) and ending upon the latest of (a) the date on which there is no Valid Claim (as such term is applied mutatis mutandis to Sanofi Sole Program Patents) of a Sanofi Sole Program Patent that would be infringed by the sale of such Termination Product in such country; (b) the expiration of any Regulatory Exclusivity granted with respect to such Termination Product in such country[***] and (II) with respect to a particular country and a particular Termination Product that is subject of the royalty obligations under Section 12.3(c)(ii)B(2) or Section 12.3(c)(ii)B(3), the period of time commencing upon the First Commercial Sale of such Termination Product in such country (by RevMed or its Affiliates or sublicensees) and ending upon the latest of (a) the expiration of any Regulatory Exclusivity granted with respect to such Termination Product in such country; and (b) [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Upon any termination of this Agreement, RevMed shall pay to Sanofi any amounts owed to Third Parties under license agreements to which Sanofi is a party that grant Sanofi a license under such Third Party's Patent Rights or Know-How that is sublicensed to RevMed pursuant to Section 12.3(c)(ii)A, unless RevMed declines in writing to obtain such sublicense. \"Post-Termination Royalty Term\" means: (I) with respect to a particular country and a particular Termination Product that is the subject of the royalty obligations under Section 12.3(c)(ii)B(1), the period of time commencing upon the First Commercial Sale of such Termination Product in such country (by RevMed or its Affiliates or sublicensees) and ending upon the latest of (a) the date on which there is no Valid Claim (as such term is applied mutatis mutandis to Sanofi Sole Program Patents) of a Sanofi Sole Program Patent that would be infringed by the sale of such Termination Product in such country; (b) the expiration of any Regulatory Exclusivity granted with respect to such Termination Product in such country[***] and (II) with respect to a particular country and a particular Termination Product that is subject of the royalty obligations under Section 12.3(c)(ii)B(2) or Section 12.3(c)(ii)B(3), the period of time commencing upon the First Commercial Sale of such Termination Product in such country (by RevMed or its Affiliates or sublicensees) and ending upon the latest of (a) the expiration of any Regulatory Exclusivity granted with respect to such Termination Product in such country; and (b) [***].",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "The auditing Party shall bear the full cost of such audit unless such audit reveals an underpayment by the audited Party that resulted from a discrepancy in the financial report provided by the audited Party for the audited period, which underpayment was more than [***] percent of the amount set forth in such report, in which case the audited Party shall reimburse the auditing Party for the costs for such audit.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "The auditing Party shall bear the full cost of such audit unless such audit reveals an underpayment by the audited Party that resulted from a discrepancy in the financial report provided by the audited Party for the audited period, which underpayment was more than [***] percent of the amount set forth in such report, in which case the audited Party shall reimburse the auditing Party for the costs for such audit.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon reasonable prior notice of the other Party, but in any event at least [***] prior notice, each Party shall and shall cause its Affiliates and its and their Sublicensees to permit an independent auditor of international prominence, selected by the auditing Party and reasonably acceptable to the audited Party, to audit the books and records maintained pursuant to Section 9.8 for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, by or to the audited Party pursuant to this Agreement or any Ancillary Agreement. Such audit shall not occur more than [***] in a given Calendar Year, unless for cause, and shall not concern books and records relating to a period more than [***] preceding the current Calendar Year.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon reasonable prior notice of the other Party, but in any event at least [***] prior notice, each Party shall and shall cause its Affiliates and its and their Sublicensees to permit an independent auditor of international prominence, selected by the auditing Party and reasonably acceptable to the audited Party, to audit the books and records maintained pursuant to Section 9.8 for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, by or to the audited Party pursuant to this Agreement or any Ancillary Agreement. Such audit shall not occur more than [***] in a given Calendar Year, unless for cause, and shall not concern books and records relating to a period more than [***] preceding the current Calendar Year.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "RevMed entered into a written agreements with prior to the Effective Date, such right of Sanofi shall be to the extent RevMed has the right to permit Sanofi to do so under such written agreements, and provided further, that RevMed shall use Commercially Reasonable Efforts to secure such right for Sanofi where one does not exist).",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "RevMed entered into a written agreements with prior to the Effective Date, such right of Sanofi shall be to the extent RevMed has the right to permit Sanofi to do so under such written agreements, and provided further, that RevMed shall use Commercially Reasonable Efforts to secure such right for Sanofi where one does not exist).",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Audit Rights_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "In addition, Sanofi shall have the right to conduct customary reviews and audits of RevMed and its Affiliates and subcontractors (provided that, with respect to Permitted Contractors or Researchers that",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "In addition, Sanofi shall have the right to conduct customary reviews and audits of RevMed and its Affiliates and subcontractors (provided that, with respect to Permitted Contractors or Researchers that",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Uncapped Liability_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a partyâs liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "NOTHING IN THIS SECTION 14.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 14.1 OR SECTION 14.2, OR DAMAGES AVAILABLE FOR A PARTY'S BREACH OF ITS OBLIGATIONS RELATING TO CONFIDENTIALITY UNDER ARTICLE XI OR INTELLECTUAL PROPERTY UNDER ARTICLE X.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Uncapped Liability_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a partyâs liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "NOTHING IN THIS SECTION 14.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 14.1 OR SECTION 14.2, OR DAMAGES AVAILABLE FOR A PARTY'S BREACH OF ITS OBLIGATIONS RELATING TO CONFIDENTIALITY UNDER ARTICLE XI OR INTELLECTUAL PROPERTY UNDER ARTICLE X.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Cap On Liability_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES OR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Cap On Liability_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES OR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Insurance_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party shall procure and maintain insurance, including product liability insurance, with respect to its activities hereunder and under the Ancillary Agreements and which is consistent with normal business practices of companies similarly situated at all times during which any SHP2 Inhibitors or Product is being clinically tested in human subjects or commercially distributed or sold.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Insurance_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party shall procure and maintain insurance, including product liability insurance, with respect to its activities hereunder and under the Ancillary Agreements and which is consistent with normal business practices of companies similarly situated at all times during which any SHP2 Inhibitors or Product is being clinically tested in human subjects or commercially distributed or sold.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Insurance_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party shall provide the other Party with evidence of such insurance upon request and, in the case of RevMed, shall provide Sanofi with written notice at least [***] prior to the cancellation, non-renewal or material changes in such insurance.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.1",
          "bbox": [
            2831.0,
            283.0,
            3050.0,
            322.0
          ],
          "confidence": 0.9973166584968567
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            281.0,
            365.0,
            3030.0,
            407.0
          ],
          "confidence": 0.9984135031700134
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            279.0,
            424.0,
            1715.0,
            460.0
          ],
          "confidence": 0.9879018664360046
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2746.0,
            552.0,
            3053.0,
            601.0
          ],
          "confidence": 0.9998288154602051
        },
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ],
          "confidence": 0.9983361959457397
        },
        {
          "text": "AGREEMENT",
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ],
          "confidence": 0.999543309211731
        },
        {
          "text": "8, 2018 (the \"Execution Date\"), by and between Revolution Medicines, Inc., a corporation organized and existing under the laws of Delaware, having its",
          "bbox": [
            275.0,
            857.0,
            3003.0,
            901.0
          ],
          "confidence": 0.9882179498672485
        },
        {
          "text": "principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (\"RevMed'), and Aventis, Inc., a corporation organized and existing under",
          "bbox": [
            277.0,
            912.0,
            3007.0,
            958.0
          ],
          "confidence": 0.9925541281700134
        },
        {
          "text": "the laws of Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (\"Sanofi''). Sanofi and RevMed are referred to in this Agreement",
          "bbox": [
            279.0,
            970.0,
            2992.0,
            1007.0
          ],
          "confidence": 0.9895532131195068
        },
        {
          "text": "individually as a \"Party'' and collectively as the \"Parties.\"",
          "bbox": [
            277.0,
            1021.0,
            1338.0,
            1062.0
          ],
          "confidence": 0.9849437475204468
        },
        {
          "text": "RECITALS",
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ],
          "confidence": 0.9994770288467407
        },
        {
          "text": "WHEREAS, RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed",
          "bbox": [
            388.0,
            1292.0,
            3011.0,
            1336.0
          ],
          "confidence": 0.9958732724189758
        },
        {
          "text": "to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine",
          "bbox": [
            275.0,
            1349.0,
            2880.0,
            1392.0
          ],
          "confidence": 0.9957889914512634
        },
        {
          "text": "phosphatase 2;",
          "bbox": [
            281.0,
            1407.0,
            556.0,
            1445.0
          ],
          "confidence": 0.9994167685508728
        },
        {
          "text": "WHEREAS, Sanofi is a pharmaceutical company working to develop and commercialize novel therapies;.",
          "bbox": [
            391.0,
            1511.0,
            2262.0,
            1551.0
          ],
          "confidence": 0.9935235977172852
        },
        {
          "text": "WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development and potential commercialization of such drug",
          "bbox": [
            388.0,
            1615.0,
            2963.0,
            1665.0
          ],
          "confidence": 0.997299313545227
        },
        {
          "text": "candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and",
          "bbox": [
            277.0,
            1676.0,
            2931.0,
            1718.0
          ],
          "confidence": 0.994562566280365
        },
        {
          "text": "WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and.",
          "bbox": [
            390.0,
            1783.0,
            2980.0,
            1826.0
          ],
          "confidence": 0.9972180724143982
        },
        {
          "text": "Products (as defined below), as further described herein..",
          "bbox": [
            277.0,
            1838.0,
            1294.0,
            1879.0
          ],
          "confidence": 0.9913728833198547
        },
        {
          "text": "NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which",
          "bbox": [
            386.0,
            1944.0,
            2994.0,
            1990.0
          ],
          "confidence": 0.9945974946022034
        },
        {
          "text": "are hereby acknowledged, RevMed and Sanofi hereby agree:",
          "bbox": [
            277.0,
            1999.0,
            1376.0,
            2045.0
          ],
          "confidence": 0.998602569103241
        },
        {
          "text": "Article I.",
          "bbox": [
            1586.0,
            2164.0,
            1744.0,
            2202.0
          ],
          "confidence": 0.9843589663505554
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ],
          "confidence": 0.9990476965904236
        },
        {
          "text": "The terms in this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated",
          "bbox": [
            392.0,
            2357.0,
            2985.0,
            2394.0
          ],
          "confidence": 0.9955936074256897
        },
        {
          "text": "places throughout this Agreement..",
          "bbox": [
            281.0,
            2414.0,
            906.0,
            2450.0
          ],
          "confidence": 0.9781932830810547
        },
        {
          "text": "1.1 \"Accounting Standards' means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such Person uses for its financial.",
          "bbox": [
            388.0,
            2518.0,
            2951.0,
            2560.0
          ],
          "confidence": 0.9858266115188599
        },
        {
          "text": "reporting obligations, consistently applied..",
          "bbox": [
            275.0,
            2571.0,
            1053.0,
            2619.0
          ],
          "confidence": 0.9880397319793701
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9917479157447815
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION",
          "page": 0,
          "bbox": [
            903.0,
            641.0,
            2423.0,
            678.0
          ]
        },
        {
          "text": "AGREEMENT",
          "page": 0,
          "bbox": [
            1537.0,
            698.0,
            1794.0,
            735.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 0,
          "bbox": [
            1562.0,
            1184.0,
            1771.0,
            1222.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 0,
          "bbox": [
            1530.0,
            2242.0,
            1802.0,
            2284.0
          ]
        }
      ]
    },
    {
      "id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement__Insurance_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party shall provide the other Party with evidence of such insurance upon request and, in the case of RevMed, shall provide Sanofi with written notice at least [***] prior to the cancellation, non-renewal or material changes in such insurance.",
      "page_number": 1,
      "words": [
        {
          "text": "1.2 \"Acquired Party Family' means in the case of a Change of Control of a Party or its Affiliate, such Party or such Affiliate existing immediately",
          "bbox": [
            388.0,
            294.0,
            3005.0,
            336.0
          ],
          "confidence": 0.9966010451316833
        },
        {
          "text": "prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created).",
          "bbox": [
            275.0,
            347.0,
            2211.0,
            393.0
          ],
          "confidence": 0.9962300658226013
        },
        {
          "text": "1.3 \"Acquiror Family' means in the case of a Change of Control of a Party or any of its Affiliates, the Acquiror and its Affiliates existing",
          "bbox": [
            386.0,
            453.0,
            2860.0,
            501.0
          ],
          "confidence": 0.9854333996772766
        },
        {
          "text": "immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family.",
          "bbox": [
            275.0,
            510.0,
            2828.0,
            556.0
          ],
          "confidence": 0.9933118224143982
        },
        {
          "text": "1.4 \"Act\" means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidance, guidelines and",
          "bbox": [
            388.0,
            621.0,
            2911.0,
            663.0
          ],
          "confidence": 0.994439423084259
        },
        {
          "text": "requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time.",
          "bbox": [
            276.0,
            674.0,
            2670.0,
            716.0
          ],
          "confidence": 0.990688681602478
        },
        {
          "text": "1.5 \"Affiliate\"' means, with respect to a Party or other Person, any corporation or other business entity that, directly or indirectly, through one or",
          "bbox": [
            386.0,
            782.0,
            3005.0,
            826.0
          ],
          "confidence": 0.9892186522483826
        },
        {
          "text": "more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person",
          "bbox": [
            274.0,
            839.0,
            2929.0,
            881.0
          ],
          "confidence": 0.9966422319412231
        },
        {
          "text": "controls, is controlled by or is under common control with such corporation or other business entity. For the purpose of this definition only, \"control\"",
          "bbox": [
            275.0,
            890.0,
            2980.0,
            936.0
          ],
          "confidence": 0.9940004944801331
        },
        {
          "text": "(including, with correlative meaning, the terms \"controlled by\"' and \"under the common control') means the actual power, either directly or indirectly",
          "bbox": [
            277.0,
            947.0,
            2949.0,
            990.0
          ],
          "confidence": 0.9859266877174377
        },
        {
          "text": "through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the",
          "bbox": [
            281.0,
            1005.0,
            2896.0,
            1042.0
          ],
          "confidence": 0.9968717098236084
        },
        {
          "text": "ownership of 50% or more of the voting equity of such Party or other Person, by contract or otherwise. Notwithstanding the foregoing, solely with",
          "bbox": [
            277.0,
            1056.0,
            2922.0,
            1100.0
          ],
          "confidence": 0.9981270432472229
        },
        {
          "text": "respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), \"Affiliates\" will not include (a) with respect to an entity, its",
          "bbox": [
            276.0,
            1111.0,
            2980.0,
            1153.0
          ],
          "confidence": 0.9877524375915527
        },
        {
          "text": "bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional",
          "bbox": [
            277.0,
            1168.0,
            2976.0,
            1204.0
          ],
          "confidence": 0.9865792393684387
        },
        {
          "text": "investors routinely make venture capital investments for the potential financial return on such investments and for so long as such institutional investors",
          "bbox": [
            277.0,
            1222.0,
            3043.0,
            1259.0
          ],
          "confidence": 0.9908832907676697
        },
        {
          "text": "do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its",
          "bbox": [
            276.0,
            1275.0,
            3038.0,
            1318.0
          ],
          "confidence": 0.9888575077056885
        },
        {
          "text": "assets or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor",
          "bbox": [
            276.0,
            1328.0,
            3043.0,
            1371.0
          ],
          "confidence": 0.9926310777664185
        },
        {
          "text": "in clause (a) and (b), an \"Excluded Investor\"), or (c) Affiliates of such venture capital, private equity or institutional investors that do not otherwise",
          "bbox": [
            277.0,
            1381.0,
            2933.0,
            1424.0
          ],
          "confidence": 0.9909785985946655
        },
        {
          "text": "qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).",
          "bbox": [
            277.0,
            1434.0,
            2811.0,
            1480.0
          ],
          "confidence": 0.991960346698761
        },
        {
          "text": "1.6 \"Ancillary Agreement\"' means the Co-Promotion Agreement, the Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply",
          "bbox": [
            386.0,
            1544.0,
            3041.0,
            1590.0
          ],
          "confidence": 0.9955523610115051
        },
        {
          "text": "Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement.",
          "bbox": [
            281.0,
            1603.0,
            3030.0,
            1645.0
          ],
          "confidence": 0.9931259155273438
        },
        {
          "text": "1.7 \"Antitrust Law\"' means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the",
          "bbox": [
            388.0,
            1705.0,
            3020.0,
            1752.0
          ],
          "confidence": 0.9911518692970276
        },
        {
          "text": "\"HsR Act'), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable",
          "bbox": [
            277.0,
            1763.0,
            2954.0,
            1804.0
          ],
          "confidence": 0.9805816411972046
        },
        {
          "text": "Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade",
          "bbox": [
            274.0,
            1818.0,
            2965.0,
            1860.0
          ],
          "confidence": 0.9963335990905762
        },
        {
          "text": "2",
          "bbox": [
            1649.0,
            1873.0,
            1680.0,
            1908.0
          ],
          "confidence": 0.9820916056632996
        },
        {
          "text": "Source: REVOLUTION MEDICINES, INC., S-1, 1/17/2020",
          "bbox": [
            332.0,
            4437.0,
            1441.0,
            4479.0
          ],
          "confidence": 0.9973000884056091
        }
      ],
      "multi_page": true,
      "part_of": 2
    }
  ]
}